Page: 1
Protocol Number: CA209238
IND Number: 115,[ADDRESS_703926] Number 2014-002351-26
Date: 11-Nov-[ADDRESS_703927]-2020
CLINICAL PROTOCOL CA209238
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunothe rapy with Nivolumab 
versus Ipi[INVESTIGATOR_540084]/c or S tage IV Melanoma in Subjects 
who are at High Risk for Recurrence
(CheckMate 238: CHECKpoint pathway and nivoluMAb clinical Trial  Evaluation 2238)
Revised Protocol Number: [ADDRESS_703928] Information
Anila Qureshi, MD, MPH 
Medical Monitor
 
This document 
is the confidential and proprietary information o f [COMPANY_016] 
Company and its global affiliates (BMS). By [CONTACT_52212], you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS-sponsored 
study. Any permitted disclosures will be made only on a confide ntial "need to know" basis 
within your organization or  to your independent ethics committee(s). Any other use, copying, 
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Revised Protocol No: 06
Date:  14-Oct-2020 2disclosure or dissemination of this information is strictly pro hibited unless expressly 
authorized in writing by [CONTACT_20444]. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document.  Any person who receives 
this document without due authorization from BMS is requested t o return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
to partners to which BMS has transferred obligations, eg, a Cont ract Research Organization 
(CRO).
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Revised Protocol No: 06
Date:  14-Oct-[ADDRESS_703929]-2020 The primary purpose of Revised Protocol 06 is to extend the collection of Overall Survival (OS) data for approximately 5 additional years. I n 
addition, data associated with the primary, secondary, and explo ratory 
efficacy outcomes (eg, melanoma recurrence data, data on develop ment 
of new primary melanomas and non-melanoma cancers, subsequent a nti-
cancer therapi[INVESTIGATOR_014]) will continue to be collected on Case Report Forms. 
Study drug-r elated serious adverse events (SAEs) w ill continue to be
collected, whereas follow-up surveillance imaging assessments, pl asma 
biomarker samples, and the EQ-5D questionnaire will no longer b e 
required during extended follow-up.
Administrative Letter 0315-Feb-2019 The purpose of this administrative letter is to change the Study Director 
for this study.
Administrative Letter 0219-Dec-2017 The purpose of this administrative letter is to confirm that a surveillance 
assessment is required at the month 24 time point (relative to the first 
dose of study treatment).
Revised Protocol 0526-Jan-2017 Incorporates Amendment(s) 18
Amendment 18 26-Jan-2017 The main purpose of this global amendmen t is to:
‚Ä¢Add an interim analysis of RFS after all subjects have a minimu m of 
18 months of follow-up (approximately 350 RFS events are 
anticipated at this analysis). 
‚Ä¢Change the name [CONTACT_540142]
‚Ä¢Add the Mechanism for Action for Ipi[INVESTIGATOR_125] 
‚Ä¢Confirm that also blood samples from subjects receiving Ipi[INVESTIGATOR_540085]-Drug Antibody 
(ADA).   
Revised Protocol 0404-Aug-2016 Incorporates Amendment(s) 17
Amendment 17 04-Aug-2016 The main purpose of this global amendment is to:
‚Ä¢Addition of Adrenocorticotropic hormone (ACTH) test at Week 45 
in subjects receiving ipi[INVESTIGATOR_125]/ipi[INVESTIGATOR_125]-placebo at Week 48  
(Note: All subjects will have completed 36 weeks of treatment prior to implementation of this amendment.)
‚Ä¢Clarify that the minimum time between dosing visits is 12 days 
between Nivolumab administrations
‚Ä¢Add information on surveillance scan requirements in case the 
patient discontinues and starts new systemic therapy. 
‚Ä¢Update the contraception section
‚Ä¢Updates in the treatment algorithms
Revised 
Protocol 0324-Feb-2016 Incorporates Amendment(s) 16
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Revised Protocol No: 06
Date:  14-Oct-2020 4Document Date of Issue Summary of Change
Amendment 16 24-Feb-2016 The main purpose of this global amendmen t is to:
1) Increase the vi sit window from ¬±2 days to ¬±3 days for all dosing 
visits, except for Week 24, Week 36 and Week 48 where the visit  
window will increase from ¬±2 days to ¬±7 days.
2) Clarify that the minimum time between dosing visits is 12 days
3) Revise and clarify the Prohibited and /or Restricted Treatmen ts
4) Update the acceptable methods of contraception
Revised 
Protocol 0206-Aug-2015 Incorporates Amendment(s) 15
Amendment 15 06-Aug-2015 The main purpose of this global amendmen t is to:
1) Incorporate the definition of immune-mediated adverse events
2) Incorporate the Adverse Event Management Algorithms for 
Immuno-oncology Agents as an appendix, and updated terminology 
to be consistent throughout document
3) Clarify that follow-up of laboratory toxicities will continue until 
toxicities resolve, return to baseline, or are deemed irreversi ble 
based on on-site/local laboratory results.
4) Clarify that follow-up of immune-mediated adverse drug reactio ns 
will continue until toxicities resolve, return to baseline, or are deemed irreversible
5) Revise the discontinuation criteria to be consistent with the 
Nivolumab USPI
6) Revise the definition of recurrence free survival to include new 
primary melanoma
7) Add censoring rules for primary analysis of recurrence free s urvival
8) Clarify that subjects will continue to be followed for recurre nces 
(until local or regional recurrences for all subjects and until distant recurrence for Stage III subjects) and survival
Revised Protocol 0102-Apr-2015 Incorporates Amendment(s) 09 and Administrative Lett er 01
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Revised Protocol No: 06
Date:  14-Oct-2020 5Document Date of Issue Summary of Change
Amendment 09 02-Apr-2015 1) The main purpose of this global amendment is to clarify the a ge 
requirement to participate in the study as the inclusion of 
adolescents may not be appropriate per local regulations.
2) Additional clarifications have been made to other 
inclusion/exclusion criteria.
3) There is also a new requirement regarding additional sample 
collection (serum, and biopsy of affected organ) for biomarker 
analysis. This collection will be done upon occurrence of ‚â• Grade 3 
drug-related AE and lab abnormalities regarded as a drug relate d 
SAE when clinically safe and feasible
4) This amendment will also be used to implement recent changes in 
the program level protocol template as well as changes to the 
standard protocol model document
5) This amendment applies to all subjects
Administrative 
Letter 0121-Jan-2015 1) IND Number 115,195
2) The title of Section 3.3.1, Item 2 should read ‚ÄúTarget Popula tion‚Äù
3) First survival follow-up visit will take place 3 months after  Follow-up 
2
Original 
Protocol11-Nov-2014 Not applicable
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
SYNOPSIS
Clinical Protocol CA209238
Protocol Title :  A Phase 3, Randomized, Double- blind Study of Adjuvant Immuno therapy with Nivolumab versus 
Ipi[INVESTIGATOR_540084]/c or Stage IV  Melanoma in Subjects who are at High Risk for 
Recurrence.
(CheckMate 238: CHECKpoint pathway and nivoluMAb clinical Trial  Evaluation 238)
Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational 
Product(s ):
Ipi[INVESTIGATOR_125] 10 mg/kg/dose IV q3 weeks x 4 doses, then 10 mg/kg/d ose IV q12 weeks s tarting at week 24 or
Nivolumab 3 mg/kg/dose IV q2 weeks 
Treat subjects un til disease recurrence, un acceptable toxicity or subject withdrawal of consent, with a ma ximum of 
1 year of treatment.Study Phase:  3
Research Hypothesis:  Treatment with nivolumab will improve recurrence-free survival as compared to ipi[INVESTIGATOR_540086]/c or Stage IV no evidence of disease (NED) melanoma who are at high 
risk for recurrence.Objectives: Primary: 
‚Ä¢To compare the efficacy, as measured by [CONTACT_540109] l (RFS), provided by [CONTACT_540110][INVESTIGATOR_540087]/c or Stage IV NED melanoma who are at high-risk 
for recurrence.
Secondary :
‚Ä¢To compare the overall survival of nivolumab vs ipi[INVESTIGATOR_62607] s ubjects with completely resected Stage IIIb/c or 
Stage IV NED melanoma who are at high risk for recurrence;
‚Ä¢To assess the overall safety and tolerability of nivolumab and ipi[INVESTIGATOR_540088]/c or Stage IV NED melanoma who are at high risk for re currence;
‚Ä¢To evaluate whether PD-L1 expression is a predictive biomarker for RFS;
‚Ä¢To evaluate the Health Related Quality of Life (HRQoL) as assessed by [CONTACT_540111] (EORTC) QLQ-C30.
Revised Protocol No: 06
Date: 14-Oct-2020 10
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Study Design:  
This is a Phase 3, randomized, double-blinded study of nivoluma b versus ipi[INVESTIGATOR_540089] ( ‚â•15 years) with 
complete resection Stage IIIb/c or Stage IV NED melanoma at high risk for recurrence. 
Approximately 800 subjects will be randomized 1:1 and stratifie d by [CONTACT_4002]-L1 status (positive vs negative/indeterminate) 
and American Joint Committee on Cancer (AJCC) stage.
Dose reductions will not be allowed.Subjects will be treated with one of the following: Arm A: ipi[INVESTIGATOR_125]: 10 mg/kg IV q3 weeks for 4 doses, then q12 we eks starting at Week 24 with nivolumab 
placebo IV q2 weeks Arm B: nivolumab 3mg/kg IV q2 weeks with ipi[INVESTIGATOR_540090] q3weeks for [ADDRESS_703930] withdrawal of consent with a 
maximum of 1 year of treatment.
Note: As of Dec-2016, all subjects in both treatment groups were  off study treatment.
Study Population:  High risk, completely resected Stage IIIb/c and IV melanoma subj ects.
Key Inclusion Criteria:
‚Ä¢At least 15 years of age
‚Ä¢Except: where local regulations and/or institutional policies d o not allow for subjects < 18 years of age (pediatric 
population) to participate. For those sites, the eligible subje ct population is ‚â• 18 years of age.
‚Ä¢All subjects must be either Stag e IIIb/c or Stage IV AJCC (7th edition) and have histologically confirmed 
melanoma that is completely surgically resected in order to be eligible. Subjects must have been surgically 
rendered free of disease with negative margins on resected specimens. Please refer to  Appendix 1 for description 
of AJCC 7th editions of TNM and staging.
‚Ä¢If Stage III melanoma (whether Stage IIIb or IIIc) the subjects  usually have clinically d etectable lymph nodes that 
are confirmed as malignant on the pathology re port and/or ulcerated primary lesions. Sub jects who are ‚ÄúN2c‚Äù 
classification with 2-3 metastatic nodes and in transit metasta ses/satellites without metastatic nodes, or, 
‚ÄúN3‚Äùclassification with any ‚ÄúT‚Äù and 4+ metastatic nodes, or matted nodes, or in transit metastases/satellites with metastatic nodes are eligible. The pathology report for both S tage IIIb and IIIc must be reviewed, signed and 
dated by [CONTACT_093]; this process will be confirmed during  the IVRS randomization call. Clinically detectable 
lymph nodes are defined as:
1) a palpable node (confirmed as malignant by [CONTACT_56618])High Risk, 
completely 
resectedStage IIIb/c 
Stage  IV 
NED melanomaRandomize 1:1
Stratify by
‚Ä¢Stage
‚Ä¢PD-L1 statusArm A (n = 400)Ipi[INVESTIGATOR_125] 10 mg/kg IV  q3 wks for 4 doses
then q12 wks starting at Wk 24
and
Nivolumab placebo IV q2 wks
Arm B (n = 400)
Nivolumab 3 mg/kg IV q2 wks
andIpi[INVESTIGATOR_540090] q3 wks for  4 doses
Then q12 wks starting at Wk 24Follow-up
Secondary
endpoint OS
For both arms, the treatment dur ation is maximum one year.
Revised Protocol No: 06
Date: 14-Oct-2020 11
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
2) a non-palpable but enlarged lymph node by [CONTACT_3610] (at least 1 5 mm in short axis) and confirmed as malignant 
by [CONTACT_56618]
3) a PET scan positive lymph node of any size confirmed by [CONTACT_540112]
4) evidence of pathologically macrometastatic disease in one or more lymph nodes defined by [CONTACT_540113] 1cm in diameter
If Stage IV melanoma, the pathology report confirming negative margins must be reviewed, dated, and signed by 
[CONTACT_98653].
‚Ä¢Complete resection of Stage III disease that is documented on t he surgical and pathology reports or complete 
resection of Stage IV disease with margins negative for disease that is documented on the pathology report.
‚Ä¢Complete resection must be performed within 12 weeks prior to randomization
‚Ä¢All subjects must have disease-free status documented by a comp lete physical examination and imaging studies 
within [ADDRESS_703931], abdomen, 
pelvis and all known sites of resected disease in the setting o f Stage IIIb/c or Stage IV disease, and brain magnetic 
resonance (MRI) or CT (brain CT allowable if MRI is contraindic ated or if there is no known history of resected 
brain lesions). 
‚Ä¢Tumor tissue from the resected site of disease must be provided  for biomarker analyses. In order t o be ra ndomized, 
a subject must have a PD-L1 expression classification (positive , negative/or indeterminate) as determined by a 
central lab.
Key Exclusion Criteria: 
‚Ä¢History of ocular/uveal melanoma
‚Ä¢Subjects with active, known, or suspected autoimmune disease. S ubjects with type I d iabetes mellitus, residual 
hypothyroidism due to autoimmune thyroiditis only requiring hor mone replacement, skin disorders (such as 
vitiligo, psoriasis, or alopecia) not requiring systemic treatm ent are permitted to enroll.
‚Ä¢Subjects with previous non-melanoma malignancies are excluded u nless a complete remission was achieved at 
least [ADDRESS_703932] udy entry and no add itional therapy is required or anticipated to be required durin g the 
study period (exceptions include but are not limited to, non-me lanoma skin cancers; in situ bladder cancer, in situ 
gastric cancer, in situ colon cancers; in situ cervical cancers/dysplasia; or breast carcinoma in situ)
‚Ä¢Subjects with a condition requiring systemic treatment with eit her corticosteroids (‚â• 10 mg daily prednisone or
equivalent) or other immunosuppressive medications within 14 da ys of study drug administratio n. Inhaled or 
topi[INVESTIGATOR_540091].
‚Ä¢Prior therapy for melanoma except surgery for the melanoma lesi on(s) and/or except for adjuvant rad iation 
therapy (RT) after neurosurgical resection for central nervous system (CNS) lesions and except for prior adjuvant 
interferon (see qualifier below). Specifically subjects who rec eived prior therapy with interferon, anti-PD-1, anti-
PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipi[INVESTIGATOR_199885] T cell co-stimulation or checkpoint path ways) are not eligible.
i) Prior treatment with adjuvant interferon is allowed if completed ‚â•6 months prior to randomization.
Revised Protocol No: 06
Date: 14-Oct-2020 12
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] 
Products (Non-IP/Non-IMP) as listed:
Study Drug for CA209238
Medication Potency IP/Non-IP 
BMS-936558-01
(Nivolumab) Solution for
Injection100 mg (10 mg/mL) IP
Ipi[INVESTIGATOR_540092]200 mg (5 mg/mL) IP
0.9% Sodium Chloride for 
InjectionN/A IP
5% Dextrose for Injection N/A IP
Study Assessments: Recurrence-free surviv al is the primary e ndpoint of the trial. It is defined as the date between 
the date of randomization and the date of first recurrence (loc al, regional or distant metastasis), new primary 
melanoma, or death (whatever the cause), whichever occurs first.  Subjects will be assessed for recurrence (until local, 
regional, or distant recurrence (whichever comes first) for Stag e IV subjects and until distant recurrence for Stage III 
subjects) by [CONTACT_540114]:
‚Ä¢Screening. 
‚Ä¢Treatment Period: Every 12 weeks ( ¬±7 days) from first dose of study drug through 12 months (relativ e to the 
first dose of study drug)  
‚Ä¢Follow-up Period: 
‚àíEvery 12 weeks ( ¬±7 days) through 12 month s for subjects who discontinued early f rom treatmen t (relative 
to the first dose of study drug)  
‚àíEvery 12 weeks ( ¬±14 days) if > 12 months through 24 months (relative to the first dose of study drug)  
‚àíEvery 6 months ( ¬±4 weeks) if > 24 months through and up to Year 5 (relative to the  first dose of study drug).
Although surveillance assessments will not be conducted beyond Year 5, data on recurrence of melanoma 
(loco-regional and distant), as well as development of new prim ary melanomas and non-melanoma cancers 
will continue to be collected in the respective Case Report Form s for an additional 5 years, for a total study 
duration of approximately 10 years.
Statistical Considerations: 
Sample Size: The sample size is calculated to compare RFS between subjects r andomized to receive 
nivolumab vs ipi[INVESTIGATOR_125]. Approximately [ADDRESS_703933] been ran domized to the two treatment arms in a 1:[ADDRESS_703934] 85% power to detect a hazard ratio of 0.75 wit h an overall type I error of 0.05 (two-sided).
Endpoints:   
Primary Endpoint: Recurrence Free Survival in all randomized subjects is the prim ary endpoint for this study.
Revised Protocol No: 06
Date: 14-Oct-2020 13
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Secondary Endpoint: Overall survival is a key secondary endpoint. If RFS superiorit y is demonstrated, OS will be 
tested hierarchically.  
Analyses:   The primary analysis of RFS in all randomized subjects will b e conducted using a two-sided log-
rank test stratified by [CONTACT_4002]-L1 status and stage. The hazard rati o and corresponding two-sided (1-adjusted Œ±)% 
confidence interval (CI) will be estimated using a Cox proporti onal hazards model, with treatment arm as a covariate, 
stratified by [CONTACT_540115]. RFS medians with 95% CIs and RFS rates at 6, 12, 18, 24, and 36 months with 95% 
CIs will be estimated using Kaplan-Meier methodology.
An interim analysis of RFS w ill be conducted af ter all subjects  have a minimum of [ADDRESS_703935] number of RFS event s using Lan-DeMets alpha spending function with 
O‚ÄôBrien-Fleming boundaries. No interim analysis of OS will be p erformed at this time.
Revised Protocol No: 06
Date: 14-Oct-2020 14
7.0 Approved 930084592 7.0v
TABLE OF CONTENTS 
  
TITLE PAGE ................................................................................................................  
DOCUMENT HISTORY .............................................. ................................................  
  
  
SYNOPSIS ...................................................... ..............................................................  
TABLE OF CONTENTS ..............................................................................................  
1 INTRODUCTION AND STUDY RATIONALE ............................ .........................  
  
  
1.3 Objectives(s) ............................................. ........................................................  
1.3.1 Primary Objectives ..................................................................................  
1.3.2 Secondary Objectives ...............................................................................  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
  
  
  
  
  
  
  



Clinical Protocol
BMS-936558CA209238
nivolumab
Revised Protocol No: 06Date: 14-Oct-[ADDRESS_703936]/Independent Ethics Committee ... ..........................  
2.[ADDRESS_703937] ............. ..................................  
4.5.1 Dosing Schedule.......................................................................................  
4.5.2 Antiemetic Premedications ......................................................................  
4.5.3 Dose Delay Criteria .................................................................................  
4.5.4 Dose Omission Criteria for Nivolumab or Ipi[INVESTIGATOR_125] ...........................  
[IP_ADDRESS] Adverse Event Management Algorithms for Immuno-Oncology 
Agents ....................................................................................................  
4.5.5 Dose Modifications ..................................................................................  
4.5.6 Criteria to Resume Treatment ..................................................................  
4.5.7 Discontinuation Criteria ..........................................................................  
4.5.8 Treatment of Nivolumab or Ipi[INVESTIGATOR_222008] ......  
4.6 Blinding/Unblinding .........................................................................................  
4.7 Treatment Compliance ...................................... ................................................  
4.8 Destruction of Study Drug ................................. ...............................................  
4.9 Return of Study Drug ........................................................................................  
5 STUDY ASSESSMENTS AND PROCEDURES ............................ .........................  
5.1 Flow Chart/Time and Events Schedule ....................... ......................................  
5.1.1 Retesting During Screening or Lead-in Period .......................................  
5.2 Study Materials .................................................................................................  
5.3 Safety Assessments ........................................ ...................................................  































Clinical Protocol
BMS-936558CA209238
nivolumab
Revised Protocol No: 06Date: 14-Oct-[ADDRESS_703938] Result Abnormalities ..............................................................  
6.4 Pregnancy ................................................. .........................................................  
6.5 Overdose .................................................. .........................................................  
6.6 Potential Drug Induced Liver Injury (DILI) ................ .....................................  
6.7 Other Safety Considerations ............................... ..............................................  
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES
.................................................................................................................................  
8 STATISTICAL CONSIDERATIONS................................... ....................................  
8.1 Sample Size Determination ................................. ..............................................  
8.2 Populations for Analyses .................................. ................................................  
8.3 Endpoints ..........................................................................................................  
8.3.1 Primary Endpoint(s) ................................................................................  
8.3.2 Secondary Endpoint(s) .............................................................................  
  
8.4 Analyses ............................................................................................................  
8.4.1 Demographics and Baseline Characteristics...........................................  
8.4.2 Efficacy Analyses .....................................................................................  
[IP_ADDRESS] Primary Endpoint Methods .............................................................  
[IP_ADDRESS] Secondary Endpoint Methods .........................................................  
8.4.3 Safety Analyses.........................................................................................  
  
  
8.4.6 Outcomes Research Analyses ..................................................................  
8.5 Interim Analyses and Hierarchical Testing ................. ......................................  
9 STUDY MANAGEMENT ........................................................................................  



























Clinical Protocol
BMS-936558CA209238
nivolumab
Revised Protocol No: 06Date: 14-Oct-2020 17
7.0 Approved 930084592 7.0v

9.1 Compliance ................................................ .......................................................  
9.1.1 Compliance with the Protocol and Protocol Revisions ...........................  
9.1.2 Monitoring ...............................................................................................  
[IP_ADDRESS] Source Documentation ....................................................................  
9.1.[ADDRESS_703939] OF ABBREVIATIONS ..................................................................................  
  
  
  
  
  
 








Clinical Protocol
BMS-936558CA209238
nivolumab
Revised Protocol No: 06Date: 14-Oct-2020 18
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
1 INTRODUCTION AND STUDY RATIONALE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
1.3
Objectives(s)
1.3.1 Primary Objectives
‚Ä¢To compare the efficacy, as measured by [CONTACT_540116], provided by [CONTACT_20382] v ersus ipi[INVESTIGATOR_540093]/c or Stage IV NED melanoma who are at high 
risk for recurrence.
Revised Protocol No: 06
Date: 14-Oct-2020 19
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
1.3.2 Secondary Objectives
‚Ä¢To compare the overall survival of nivolumab vs ipi[INVESTIGATOR_540094]/c or Stage IV NED melanoma who are at high r isk for recurrence.
‚Ä¢To assess the overall safety and tolerability of nivolumab and ipi[INVESTIGATOR_540095]/c or Stage IV NED melanoma who ar e at high risk for 
recurrence.
‚Ä¢To evaluate whether PD-L1 expression is a predictive biomarker for RFS.
‚Ä¢To evaluate the Health Related Qu ality of Life (HRQoL) as assessed by [CONTACT_540117] (EORTC) QLQ-C30.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No: 06
Date: 14-Oct-2020 20
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
 
 
 
 
   
2
ETHICAL CONSIDERATIONS
2.1 Good Clinical Practice
This study will be conducted in accordance with Good Clinical P ractice (GCP ), as defined by [CONTACT_20417] (ICH) and in accordan ce with the ethical principles 
underlying European Union Directive 2001/20/EC and the [LOCATION_002] Code of Federal 
Regulations, Title 21, Part 50 (21CFR50).
The study w ill be c onducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will r eceive Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) approval/favorabl e opi[INVESTIGATOR_122339].
All potential serious breaches must be reported to BMS immediately. A serious breach is a breach 
of the conditions and principles of GCP in connection with the study or the protocol, which is 
likely to affect, to a significant degree, the safety or physic al or mental integrity of the subjects of 
the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by [CONTACT_8640], training, and 
experience to perform their respective tasks.This study will not use the services of study personnel where s anctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medi cal licensure, debarment). 
2.[ADDRESS_703940]/Independent Ethics Committee 
Before study initiation, the investigator must have written and  dated approval/favorable opi[INVESTIGATOR_20291]/IEC for the protocol, consent form, subject recrui tment materials (eg, 
advertisements), and any other written information to be provid ed to subjects. The investigator or 
BMS should als o provide the IRB/IEC with a copy of the  Investigator Brochure or product labeling 
information to be provided to subjects and any updates. 
The investigator or BMS should provide the IRB/IEC with reports, updates and other information 
(eg, expedited safety reports, amendments, and administrative l etters) according to regulatory 
requirements or institution procedures.
2.[ADDRESS_703941] ensure that subjects are clearly and fully i nformed about the purpose, potential 
risks, and other critical issues regardi ng clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about th e purpose, potential risks, and other 
critical issues regarding clinical studies in which the subject volunteers to participate. 
Revised Protocol No: 06
Date: 14-Oct-2020 37
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
BMS will provide the investigator with an appropriate (ie, Global or Loc al) sample informed 
consent form which will include all elements re quired by [CONTACT_12212], G CP and applicable regulatory 
requirements. The sample informed consent form w ill adhere to th e ethical principles that have 
their origin in the D eclaration of Helsinki.
Investigators must:
1) Provide a copy of the consent form and written information ab out the study in the language in 
which the subject is most proficient prior to clinical study pa rticipation. The language must be 
non-technical and easily understood. 
2) Allow time necessary for subject or subject's legally accepta ble representative to inquire about 
the details of the study.
3) Obtain an informed consent signed and personally dated by [CONTACT_29159]'s legally 
acceptable representative and by [CONTACT_35884] i nformed consent discussion. 
4) Obtain the IRB/IEC‚Äôs written approval/favorable opi[INVESTIGATOR_540096], prior  to the beginning of the study, 
and after any revisions are completed for new information.
5) If informed consent is initially given by a subject‚Äôs legally  acceptable representative or legal 
guardian, and the subject subsequently becomes capable of makin g and communicating his or 
her informed consent during the study, consent must additionall y be obtained from the subject.
6) Revise the informed consent whenever important new informatio n becomes available that is 
relevant to the subject's consent. The investigator, or a perso n designated by [CONTACT_093], 
should fully  inform the subject or the subject's legally accept able representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
subject's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects mus t be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements , the subjects' signed ICF and, in the 
US, the subjects‚Äô signed HIPAA Authorization.
The consent form must also include a statement that BMS and regu latory authorities have direct 
access to subject records. 
For minors, according to local legislation, one or both parents  or a legally acceptable representative 
must be informed of the study procedures and must sign the info rmed consent form approved for 
the study prior to clinical study participation. The explicit w ish of a minor, who is capable of 
forming an opi[INVESTIGATOR_334459] t o refuse participation in, or to be withdrawn 
from, the clinical study at any time should be considered by [CONTACT_3433] e investigator. 
Minors who are judged to be of an age of reason must also give their written assent.
The rights, safety, and well-being of the study subjects are th e most important considerations and 
should prevail over interests of science and society.
Revised Protocol No: 06
Date: 14-Oct-2020 38
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
3 INVESTIGATIONAL PLAN
3.1 Study Design and Duration
The study design schematic is presented in  Figure 3.1-1.
Figure 3.1-1: Study Design Schematic
The subjects will be treated in both arms until disease recurrenc e, unacceptable toxicity, or subject
withdrawal of consent with a maximum of 1-year total duration o f study medication.
Note: As of Dec-2016, all subjects in both treatment groups wer e off study treatment.
This study will consist of three phases: screening, treatment, and follow-up.
For a complete list of study required procedures, please refer to Section 5 . 
Screening Phase:
‚Ä¢Begins by [CONTACT_52225]‚Äôs initial eligibility and si gning of the informed consent form 
(ICF).
‚Ä¢Subject is enrolled using the IVRS. 
‚Ä¢Subject is assessed for complete study eligibility within the required timeframe found in  Table 
5.1-1 .
‚Ä¢A pregnancy test for WOCBP shoul d be documented within [ADDRESS_703942] dose of study medication. 
‚Ä¢Tumor tissue must be received at the Central Laboratory for PD- L1 IHC testing in order for 
the subject to be randomized. PD-L1 status will be used as a st ratification factor. 
‚Ä¢If Stage III, the pathology reports of clinically detectable node(s) confirming malignancy must 
be reviewed, dated, and signed by [CONTACT_98653].
‚Ä¢If Stage IV, the pathology report  confirming negative margins m ust be reviewed, dated, and 
signed by [CONTACT_98653].High Risk, 
completely 
resectedStage IIIb/c Stage  IV NED melanomaRandomize 1:1
Stratify by
‚Ä¢Stage
‚Ä¢PD-L1 statusArm A (n = 400)
Ipi[INVESTIGATOR_125] 10 mg/kg IV  q3 wks for 4 doses
then q12 wks starting at Wk 24
andNivolumab placebo IV q2 wks
Arm B (n = 400)
Nivolumab 3 mg/kg IV q2 wks
andIpi[INVESTIGATOR_540090] q3 wks for  4 doses
Then q12 wks starting at Wk 24Follow-up
Secondary
endpoint OS
For both arms, the treatment dur ation is maximum one year.
Revised Protocol No: 06
Date: 14-Oct-2020 39
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Treatment Phase:
‚Ä¢Following confirmation of the subject‚Äôs eligibility, the random ization call to the IVRS can be 
made. The subject is randomly assigned to the ipi[INVESTIGATOR_125] 10 mg/ kg arm and placebo arm 
(Arm A), or the nivolumab 3 mg/kg arm and placebo arm (Arm B).
‚Ä¢Within [ADDRESS_703943] dose of study 
medication (Day  1 of W eek 1)
‚Ä¢On-study laboratory assessments should be drawn within 72 hours prior to dosing
‚Ä¢Adverse event assessments should be documented at each clinic visit and WOCBP must have 
a pregnancy test every four weeks ¬±1 week.
‚Ä¢PK samples and immunogenicity samples will be collected accordi ng to the schedule in  Table 
5.5-1
‚Ä¢Treated subjects will be evaluated for recurrence every 12 week s ¬±7 days 
‚Ä¢Patient Reported Outcome (PRO) instruments must be completed af ter randomization, prior to 
the dose of study thera py and according to schedule in  Table 5.1-2 , Table 5.1-3 , Table 5.1-4 , 
andTable 5.1-6 .
‚Ä¢This phase ends when the subject is discontinued early from stu dy therapy or at a maximum 
of [ADDRESS_703944] of reasons for treat ment discontinuation, see 
Section 3.5 .
Follow- up Phase:
‚Ä¢Begins after [ADDRESS_703945] from 
study therapy.
‚Ä¢Follow-up visits (See  Table 5.1-3 ) include collecti on of PK/immunogenicity samples.
‚Ä¢After completion of the first two follow-up visits, subjects wi ll be followed every 3 months for 
survival.
‚Ä¢Subjects who discontinue treatment for reasons other than recur rence will continue to have 
surveillance assessments (until local, regional, or distant recur rence (whichever comes first)
recurrence for Stage IV subjects and until distant recurrence for S tage III subjects)
‚àíSurveillance assessments should occur every 12 weeks ¬± [ADDRESS_703946] year after 
randomization, every 12 weeks ¬± 14 days during the second year,  e v e r y  
6 months ¬± [ADDRESS_703947] assessment at Year 5.
‚àíStudy-specified surveillance imaging assessments will be discont inued beyond Year 5. 
Data on recurrence of melanoma (loco-regional and distant), as well as development of 
new primary melanomas and non-melanoma cancers after Year 5 wil l continue to be 
collected in the respective Case Report Forms.
‚Ä¢Subjects will be followed for drug-related toxicities until the se toxicities resolve, return to 
baseline or are deemed  irreversible. All t oxicities will be doc umented for a minimum of 
[ADDRESS_703948] dose of study medication.
‚Ä¢PRO instruments will be completed according to the schedule in Table 5.1-6.
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703949] Study Access to Therapy
At the end of the study, BMS will not continue  to provide BMS s upplied study drug to 
subjects/investigators unless BMS chooses to extend the study. The investigator should ensure that 
the subject receives appropriate standard of care to treat the condition under study.
3.[ADDRESS_703950] be met.
3.3.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Subjects must have signed and dated an IRB/IEC approved writt en informed consent form 
in accordance with regulatory and institutional guidelines. Thi s must be obtained before 
the performance of any protocol related procedures that are not  part of normal subject care
b) Subjects must be willing and able to comply with scheduled vi sits, treatment schedule, 
laboratory tests, t umor biopsies , and other requirements of the  study.
2) Target Population
a) All subjects must be either Stage IIIb/c or Stage IV American Joint Committee on Cancer 
(AJCC) Melanoma Staging (7th edition) and have histologically co nfirmed melanoma that 
is completely surgically resected in order to be eligible.  S ubjects must have been s urgically 
rendered free of disease with negative margins on resected spec imens. Please refer to 
Appendix 1 or descript ion of AJ CC 7th editions of TNM and staging.
i) If Stage III m elanoma (whether Stage IIIb or IIIc) the subjects usually have clinically 
detectable lymph nodes that are confirmed as malignant on the pathology report and/or 
ulcerated primary lesions. Subjects who are ‚ÄúN2c‚Äù with 2-3 metas tatic nodes and in 
transit metastases/satellites without metastatic nodes, or, ‚ÄúN3‚Äù  classification with any 
‚ÄúT‚Äù and 4+ metastatic nodes, or matted nodes, or in transit met astases/satellites with 
metastatic  nodes are eligible. The p athology report for both Stage IIIb and IIIc must be 
reviewed, signed and dated by [CONTACT_093]; this process wil l be confirmed during 
the IVRS randomization call.  Clinically detectable lymph nodes  are defined as:
(1) A palpable node (confirmed as malignant by [CONTACT_56618])
(2) A non-palpable but enlarged lymph node by [CONTACT_4654] (at least 15 mm in short axis) and  
confirmed as malignant by [CONTACT_56618]
(3) A PET positive lymph node of any size confirmed by [CONTACT_56618](4) Evidence of pathol ogically macrometas tatic diseas e in one or more lymph nodes 
defined by [CONTACT_540118] 1cm in diamete r
ii) If Stage IV melanoma, the pathology report confirming negati ve margins must be 
reviewed, dated and signed by [CONTACT_540119]: 06
Date: 14-Oct-2020 41
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚ô¶For CNS lesion(s), documentation, provided by a neurosurgeon, indicating that there 
has been complete res ection of C NS lesion(s) w ill suffice as confirmation of negative 
margins  
b) All melanomas, except ocular/uveal melanoma, regardless of pr imary site of disease will 
be allowed; mucosal melanomas are eligible.
c) Complete re section of Stage III disease that is documente d on the surgical and pathology 
reports or complete resection of Stage IV disease with margins negative that is documented 
on the pathology report.
d) The last intervention demonstrating that the subject is free o f disease must be performed 
within 12 weeks prior to randomization.
e) Subjects must not have received anti-cancer treatment (for ex ample but not limited to, 
systemic, local, radiation, radiopharmaceuticals) for their mel anoma. 
3) Exceptions: Surgery for melanoma or/and post-resection brain R T if CNS metastases or/and 
prior treatment w ith adjuvant interferon under certain circumsta nces (as described in exclusion
criterion 2di)
a) All subjects must ha ve disease-free status documented by a complete physical examination 
and imaging studies within [ADDRESS_703951], abdomen, pelvis, and all known sites of  resected disease in the 
setting of Stage IIIb/c or Stage IV disease, and brain MRI (bra in CT allowable if MRI is 
contraindicated or if there is no known history of resected brai n lesions).
b) The complete set of baseline radiographic images must be avai lable before randomization.
c) ECOG performance status score of 0 or 1 ( Appendix 2 )
d) Tumor tissue from the resected site of disease must be provid ed for biomarker analyses.  
In order t o be randomized, a subject must have a PD-L1 expressi on classification (positive, 
negative, or indeterminate) as determined by [CONTACT_6626]. I f insufficient tumor tissue 
content is provided for analysis, acquisition of additional arc hived tumor tissue (block and 
/or slides) for the biomarker analysis is required.   
e) Prior treated central nervous s ystem (CNS) metastases must be  without MRI evidence of 
recurrence for at least [ADDRESS_703952] b e off imm unosuppressive 
doses of systemic steroids ( ‚â•10 mg/day prednisone or equivalent) for at least [ADDRESS_703953]-operatively.
(1) The 4-week period of stability is measured after the complet ion of the neurologic 
interventions, ie surgery and/or radiation
f) In addition to neurosurgery to treat CNS metastases, adjuvant radiation after the resection 
of CNS metastasis is allowed. Immunosuppressive doses of systemi c steroids (doses 
‚â•10 mg/day prednisone or equivalent) must be discontinued at least 14 days before study 
drug administration
g) Prior surgery that required general anesthesia must be comple ted at least 4 weeks before 
study drug administration.  Surgery  requiring local/epi[INVESTIGATOR_540097] 72 hours before study drug administration.  
h) All baseline laboratory requirements w ill be assessed and s hould be ob tained within 
[ADDRESS_703954] meet the following criteria 
Revised Protocol No: 06
Date: 14-Oct-2020 42
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
i) WBCs ‚â•2000/ŒºL
ii) Neutrophils ‚â•1500/ŒºL
iii) Pl atelets ‚â•100 x 10¬≥/ŒºL
iv) Hemoglobin ‚â•9.0 g/dL
v) Creatinine Serum creatinine ‚â§1.5 x upper limit of normal (ULN) or creatinine 
clearance > 40 mL/minute (using Cockcroft/Gault formula)
vi) AST ‚â§[ADDRESS_703955] 
vii) ALT ‚â§[ADDRESS_703956]
viii) Total Bilirubin ‚â§1.[ADDRESS_703957] (except subjects with Gilbert Syndrome who 
must have total b ilirubin < 3.0 mg/dL)
i) Subject Re-enrollment:  This study permits the re-enrollment of a subject that has 
discontinued the study as a screen failure (ie, subject has not  been randomized / has not 
been treated). If re-enrolled, the subject must be re-consented.
4) Age and Reproductive Status
a) Males and Females, ‚â•15 years of age
Except: where local regulations and/or institutional policies d o not allow for subjects 
< 18 years of age (pediatric population) to participate. For thos e sites, the eligible subject 
population is ‚â•18years of age
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units  of HCG) within 24 hours 
prior to the start of study drug.
c) Women must not be breastfeeding
d) WOCBP must agree to follow instructions for method(s) of cont raception for the duration 
of treatment with study drug (s) plus 5 half-lives of study dru g plus 30 days (duration of 
ovulatory cycle). The half-life  of nivolumab and ipi[INVESTIGATOR_540098] [ADDRESS_703958]- treatment completion
(Appendix 3 ).
e) Males who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of treatment with s tudy drug (s) plus 
5 half-lives of the study drug (s) plus 90 days (duration of spe rm turnover). The half-life 
of nivolumab and ipi[INVESTIGATOR_540098] [ADDRESS_703959]-treatment completion (Appendix 3).
f) Azoospermic males and WOCBP who are continuously not heterose xually active are 
exempt from contraceptive requirements.  However, they must sti ll undergo pregnancy 
testing as described in this section.
Investigators sh all counsel WOCBP and male sub jects who are sexually active with WOCBP on 
the importance of pregnancy prevention and the implications of an unexpected pregnancy 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703960] 
a failure rate of < 1% when used consistently and correctly. (R efer to Appendix 3 .)
3.3.2 Exclusion Criteria
1) Target Disease Exceptions
a) Subjects with carcinomatosis meningitis
b) History of ocular/uveal melanoma
2) Medical History and Concurrent Diseases
a) Subjects with previous non-melanoma malignancies are excluded  unless a complete 
remission was achieved at least 3 years prior to study entry an d no additional therapy is 
required or anticipated to be required during the study period (exceptions include but are 
not limited to, non-melanoma skin cancers; in situ bladder canc er, in situ gastric cancer, or
in situ colon cancers; in situ cervical cancers/dysplasia; or breast carcinoma in situ)
b) Subjects with active, known, or suspected autoimmune disease.  S u b j e c t s  w i t h  t y p e  I  
diabetes mellitus, residual hypothyroidism due to autoimmune th yroiditis only requiring 
hormone rep lacement, skin disorders (such as vitiligo, psoriasis, or alope cia) not requiring 
systemic treatment are permitted  to enroll.  For any cases of uncertainty, it is recommended 
that a BMS medical monitor be consulted prior to signing inform ed consent.
c) Subjects with a condition requiring systemic treatment with e ither corticosteroids (‚â• 10 mg 
daily prednisone or equivalent) or other immunosuppressive medi cations within 14 days 
of study drug administration. Inhaled or topi[INVESTIGATOR_540099].
d) Prior therapy for melanoma except surgery for the melanoma le sion(s) and except   
adjuvant RT after neurosurgical resection for CNS lesions and except for prior adjuvant 
interferon (see qualifier below). Specifically subjects who rec eived prior therapy with anti-
PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipi[INVESTIGATOR_120979]  T cell co-stimulation or 
checkpoint pathways) are not eligible.
i) Prior treatment with adjuvant interferon is allowed if comple ted ‚â•6 months prior to 
randomization
e) Treatment directed against the resected melanoma (eg, chemoth erapy, targeted agents, 
biotherapy, or limb perfusion) that is administered after the c omplete resection other than 
adjuvant radiation after neurosurgical resection.
f) Any serious or uncontrolled medical disorder or active infect ion that, in the opi[INVESTIGATOR_1070], may increase the risk associated with study parti cipation, study drug
administration, or would impair the ability of the subject to r eceive protocol therapy.
3) Physical and Laboratory Test Findings
a) Any positive test result for hepatitis B virus or hepatitis C  virus indicating acute or chronic 
infection.
Revised Protocol No: 06
Date: 14-Oct-2020 44
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
b) Known history of testing positive for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS).
4) Allergies and Adverse Drug Reaction
a) History of Grade ‚â•3 allergy to human monoclonal antibodies
5) Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated
b) Subjects who are compulsorily detained for treatment of eithe r a psychiatric or physical 
(eg, infectious disease) illness
c) Pregnant or nursing women
d) Psychological, familial, socio logical, or geographical condit ions that potentially hamper 
compliance with the study protocol and follow-up schedule; thos e conditions should be 
discussed with the subject before registration in the trial
Eligibility criteria for this study have been carefully conside red to ensure the safety of the study 
subjects and that the results of the study can be used. It is i mperative that subjects fully meet all 
eligibility criteria.
3.3.3 Women of Childbearing Potential
Women of childbearing potential (WOCBP) is defined as any femal e who has experienced 
menarche and who has not undergone surgical sterilization (hyst erectomy or bilateral 
oophorectomy) and is not postmenopausal. Menopause is defined a s [ADDRESS_703961] imulating hormone, (FSH) level > 
40mIU/mL to confirm menopause.
*Females treated with hormone repl acement therapy, (HRT) are likely to have artificia lly 
suppressed FSH levels and may re quire a washout period in order to obtain a  physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the inves tigators should use their 
judgement in checking serum FSH levels. If the serum FSH level is >40 mIU/ml at any time during 
the washout period, the woman can be considered postmenopausal:
‚àí1 week minimum for vaginal hormonal products (rings, creams, ge ls)
‚àí4 week minimum for transdermal products
‚àí8 week minimum for oral products
Other parenteral products may require washout periods as long a s 6 months.
3.4 Concomitant Treatments
3.4.1 Prohibited and/or Restricted Treatments
The following medications a re prohibited during the tr eatment and follow-up phases (before 
recurrence) of the study (unless utilized to treat a drug-relat ed adverse event):
Revised Protocol No: 06
Date: 14-Oct-2020 45
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚Ä¢Immunosuppressive agents - only until treatment discontinuation
‚Ä¢Immunosuppressive doses of systemic corticosteroids (except as s tated in Section 3.4.2 )- only 
until treatment discontinuation
‚Ä¢Any concurrent systemic anti-neoplastic therapy for the treatmen t of melanoma or a new 
malignancy (except as noted). Subjects who develop a new non-me lanoma fully resectable 
malignancy (examples include but are not limited to: in situ bl adder cancer, in situ gastric 
cancer, or in situ colon cancers; in situ cervical cancers/dyspl asia; or breast carcinoma in situ; 
or prostate carcinoma) during the study may continue receiving study drugs if the only therapy 
required is hormonal ther apy, surgery and/or rad iation (and the surgery  or radiation site does 
not overlap with a previous primary melanoma or melanoma metasta sis location). Consultation 
with the medical monitor is required once a new malignancy is d etected.
3.4.2 Permitted Therapy
Subjects are permitted the use of topi[INVESTIGATOR_2855], ocular, intra-articu lar, intranasal and inhalational 
corticosteroids (with minimal systemic absorption). Physiologic  replacement doses of systemic 
corticosteroids are permitted even if > 10 mg daily prednisone (or equivalent). A brief course of 
corticosteroids for prophylaxis (eg, for contrast dye allergy) or for treatment of non-autoimmune 
conditions (eg, delayed-type hypersensitivity reaction caused b y a contact [CONTACT_20435]) is permitted.
Intravitreal injections of vasc ular endothelial growth (VEGF) i nhibitors are permitted if used 
according to the approved ocular indication, such as macular degeneration.
3.[ADDRESS_703962] (and non-inve stigational product at the 
discretion of the investigator) for a ny of the following reasons:
‚Ä¢Subject‚Äôs request to stop study treatment
‚Ä¢Recurrence (local, regional or distant)
‚Ä¢Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opi[INVESTIGATOR_871], indicates that continued participa tion in the study is not in the best 
interest of the subject
‚Ä¢Termination of the study by [CONTACT_43899] (BMS)
‚Ä¢Loss of ability to fr eely provide consent through imprisonment or involuntarily inca rceration 
for treatment of either a psychiatric or physical (eg, infectio us disease) illness
‚Ä¢Unblinding a subject for any reason (emergency or non-emergency )
‚Ä¢Additional protocol specified reasons for discontinuation (see Section 4.5.7) .
In the case of pregnancy, the investigator must immediately not ify the BMS Medical 
Monitor/designee of this event. In most cases, the study drug w ill be permanently discontinued in 
an appropriate manner. If the investigator d etermines a possible favorable benefit/risk ratio that 
warrants continuation of study drug, a discussion between the i nvestigator and the BMS Medical 
Monitor/designee must occur.
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703963]-treat ment study follow-up or loses the 
ability to consent fr eely (ie, is imprisoned or involuntarily i ncarcerated for the treatment of either 
a psychiatric or physical illness).
If study drug is discontinued prior to the subject‚Äôs completion  of the study, the reason for the 
discontinuation must be documented in the subject‚Äôs medical rec ords and entered on the 
appropriate case report form (CRF) page.3.[ADDRESS_703964] continue to be followed for collection of outcome and /or survival follow-up data as 
required and in line with  Section [ADDRESS_703965] that surviva l data be collected on all ra ndomized subjects outside  of the protocol 
defined window (Table 5.1-7 ). At the time of this r equest, each s ubject w ill be con tacted to 
determine their survival status unless the subject has withdrawn consent for all contact. 
3.6.[ADDRESS_703966] with him /her or persons previously 
authorized by [CONTACT_20439]. Subjects sho uld notify the investigator of the 
decision to withdraw consent from future follow-up in writing , whenever possible. The 
withdrawal of consent should be explained in detail in the medi cal records by [CONTACT_093], as 
to whether the withdra wal is from further tr eatment with study drug only or also from study 
procedures and/or post treatment study follow-up, and entered o n the appropriate CRF page. In the 
event that vital status (wheth er the subject i s alive or dead) i s being measured, publicly available 
information should be used to determine vital status only as ap propriately directed in accordance 
with local law.
3.6.[ADDRESS_703967]‚Äôs medical records. If it is  determined that the subject has died, 
the site will use permissible local methods to obtain the date and cause of death.
If investigator‚Äôs use of third-party representative to assist i n the follow- up portion of  the study has 
been included in the subject‚Äôs informed consent, then the inves tigator may use a Sponsor-retained 
third-party representative to assist site staff with obtaining subject‚Äôs contact  [CONTACT_61860]
 -up po rtion of the study. The site staff and 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703968]‚Äôs medical records.
4 STUDY DRUG
Study drug includes both Investigational [Medicinal] Product (I P/IMP) and Non-investigational 
[Medicinal] Product (Non-IP/Non-IMP) and can consist of the fol lowing:
Revised Protocol No: 06
Date: 14-Oct-2020 48
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Table 4-1: Study Drugs for CA209238
Product Description / 
Class and Dosage FormPotency IP/Non-IMP Blinded or Open 
LabelPackaging/ 
AppearanceStorage Conditions
(per label)
BMS-936558-01 (Nivolumab) Solution for 
Injection100 mg (10 mg/mL) IPOpen Labela 10 mL/vial (5 or 
10 vials/carton)Store at 2¬∞ - 8¬∞C.   
Protect from light and 
freezing.
Ipi[INVESTIGATOR_404294]200 mg (5 mg/mL) IPOpen Labela 40 mL/vial 
(4 vials/carton)Store at 2¬∞ - 8¬∞C.   
Protect from light and 
freezing.
0.9% Sodium Chloride for InjectionN/A IP Open Label Various (local 
commercial product)As per active IP
5%  Dextrose for InjectionN/A IP Open Label Various (local 
commercial product)As per active IP
aThe term ‚Äúopen label‚Äù refers to the medication as it is upon rec eipt at the pharmacy.  The trial will be conducted in a double- blinded fashion.
Premedications or medications used to treat i nfusion-related r eactions should be sourced by [CONTACT_20442]. Solutions used as diluent or pl acebo (ie, 0.9% Sodium Chloride Injection or 5% Dextrose Inject ion) 
should also be sourced by [CONTACT_540120].
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703969] in some regions, is 
defined a pharmaceutical form of an active substance or placebo  being tested or used as a reference 
in a clinical study, including products already with a marketin g authorization but used or 
assembled (formulated or packaged) differently than the authori zed form, or used for an 
unauthorized indication, or when used to gain further informati on about the authorized form.
The investigational product should be stored in a secure area a ccording to local regulations. It is 
the responsibility of the investigator to ensure that investiga tional product is only dispensed to 
study subjects. The investigational product must be dispensed o nly from official study sites by 
[CONTACT_20443]. 
In this protocol, investigational products are: nivolumab, ipil imumab, nivolumab placebo (0.9% 
sodium chloride injection or 5% dextrose injection), and ipi[INVESTIGATOR_540100] (0.9% sodium 
chloride injection or 5% dextrose injection).
4.[ADDRESS_703970] storage manager should ensure that the study drug i s stored in accordance with the 
environmental conditions (temperature, light, and humidity) as determined by [CONTACT_20444]. If concerns 
regarding the quality or appearance of the study drug arise, th e study drug should not be dispensed 
and contact [CONTACT_20445].
Investigational product documentation (whether supplied by [CONTACT_20447]) must be maintained that 
includes all processes required to ensure drug is accurately ad ministered. This includes 
documentation of drug storage, administration a nd, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).For study drugs not provided by [CONTACT_540121] b y the site, storage should be in 
accordance with the product label
Infusion-related supplies (eg, IV bags, in-line filters, 0.9% s odium chloride injection, 5% dextrose 
injection) will not be supplied by [CONTACT_448301].Please refer to the current version of the Investigator Brochur e (IB) and/or phar macy reference 
sheets for complete storage, handling, dispensing, and infusion  information for nivolumab and 
ipi[INVESTIGATOR_125].
The unblinded pharmacist will obtain treatment assignment by [CONTACT_540122].
The infusion duration of nivolumab is [ADDRESS_703971] ÕÉs initial eligibility is established and informed consent has b een obtained, the 
subject must be enrolled into the study by [CONTACT_20449] o btain the subject number. Every 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703972] for enrollme nt by [CONTACT_61866]. The following information is requ ired for enrollment:
‚Ä¢Date that informed consent was obtained
‚Ä¢Date of birth
‚Ä¢Gender at birth.
Once enrolled in IVRS, enrolled sub jects that have met all eligibility criteria (the required tumo r 
tissue received and result obtained by [CONTACT_2237] a nd the pathology report approved by 
[CONTACT_093]) will be ready to be randomized through the IV RS. The ra ndomization call will be 
performed by [CONTACT_540123] y site staff. The following i nformation is required for subject 
randomization:
‚Ä¢Subject number
‚Ä¢Date of birth
‚Ä¢PD-L1 evaluable status (Note that the result of PD-L1 positive v s PD-L1 
negative/indeterminate is entered by [CONTACT_540124] n blinded to the result)
‚Ä¢AJCC Stage and M classification
‚àíStage IIIb/c
‚àíStage IV M1a-M1b
‚àíStage IV M1c.
Subjects meeting all eligibility criteria will be randomized in a 1:1 ratio to Arm A  ipi[INVESTIGATOR_125] + 
placebo or Arm  B nivolumab + placebo stratified by [CONTACT_141574] g factors: 
‚Ä¢PD-L1 status
‚Ä¢AJCC stage (M classification if Stage IV).
The exact procedures for using the IVRS will be detailed in the  IVRS manual.
4.[ADDRESS_703973] be administered within 3 business days following randomization. When study 
drugs (ipi[INVESTIGATOR_120992]) or matched placebos are to be a dministered on the same day, 
separate i nfusion bags and filters must be used for each infusion. Nivolu mab or nivolumab-placebo 
is to be administered first. Th e second infusion will always be  the ipi[INVESTIGATOR_122889]-
placebo study drug, and will start no sooner than 30 minutes af ter completion of the nivolumab or 
nivolumab-placebo infusion .
Revised Protocol No: 06
Date: 14-Oct-2020 51
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Subjects may be dosed up to ¬± 3 days before or after the schedul ed date if necessary. There should 
be a minimum of 12 days between 2 nivolumab/nivolumab-placebo ad ministrations. For dosing 
visits of Week 24, Week 36 and Week 48, subjects may be dosed u p to ¬± 7 days.
4.5.1 Dosing Schedule
The Dosing schedule is described in Table 4.5.1-1 and Table 4.5.1-2 .Weight should be used to 
calculate the dose and if the weight differs ‚â•10% from baseline, t he dose should be recalculated. 
Revised Protocol No: 06
Date: 14-Oct-2020 52
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Table 4.5.1-1: Dosing Schedule 
Day 1 
Week 1Day 1 
Week 3Day 1 
Week 4Day 1 
Week 5Day 1 
Week 7Day 1 
Week 9Day 1 
Week 10Day 1 
Week 11Day 1 
Week 13
Arm A 
Ipi[INVESTIGATOR_125]  
+ 
Nivolumab
Placebo3mg /kg 
Nivolumab-
Placebo 3 mg/kg 
Nivolumab-
Placebo10 mg/kg 
Ipi[INVESTIGATOR_125]3 mg/kg 
Nivolumab-
Placebo3mg /kg 
Nivolumab-
Placebo 3 mg/kg 
Nivolumab-
PlaceboIpi 10 mg/kg 
Ipi[INVESTIGATOR_125]3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo10 mg/kg
Ipi[INVESTIGATOR_125]10 mg/kg 
Ipi[INVESTIGATOR_251415] B 
Nivolumab 
+ 
Ipi[INVESTIGATOR_540101]3 mg/kg
Nivolumab
3 mg/kg 
Nivolumab10 mg/kg
Ipi[INVESTIGATOR_125]-
Placebo3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab
3 mg/kg 
Nivolumab10 mg/kg
Ipi[INVESTIGATOR_125]-
Placebo3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab10 mg/kg
Ipi[INVESTIGATOR_125]-
Placebo10 mg/kg
Ipi[INVESTIGATOR_125]-
Placebo
Day 1 
Week 15Day 1 
Week 17Day 1 
Week 19Day 1 
Week 21Day 1 
Week 23Day 1 
Week 24Day 1 
Week 25Day 1 
Week 27Day 1 
Week 29
Arm A 
Ipi[INVESTIGATOR_125]  
+ 
Nivolumab
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo10 mg/kg 
Ipi[INVESTIGATOR_125]3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo
Arm B 
Nivolumab 
+ 
Ipi[INVESTIGATOR_540101]3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab10 mg/kg
Ipi[INVESTIGATOR_125]-
Placebo3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab
Revised Protocol No: 06
Date: 14-Oct-2020 53
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Table 4.5.1-2: Dosing Schedule 
Day 1 
Week 31Day 1 
Week 33Day 1 
Week 35Day 1 
Week 36Day 1 
Week 37Day 1 
Week 39Day 1 
Week 41Day 1 
Week 43Day 1 
Week 45
Arm A 
Ipi[INVESTIGATOR_125]
  + 
Nivolumab
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo10 mg/kg 
Ipi[INVESTIGATOR_125]3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo
Arm B 
Nivolumab 
+ 
Ipi[INVESTIGATOR_540101]3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab10 mg/kg
Ipi[INVESTIGATOR_125]-
Placebo3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab
Day 1 
Week 47Day 1 
Week 48Day 1 
Week 49Day 1 
Week 51
Arm A 
Ipi[INVESTIGATOR_125]  
+ 
Nivolumab
Placebo3 mg/kg 
Nivolumab-
Placebo10 mg/kg 
Ipi[INVESTIGATOR_125]3 mg/kg 
Nivolumab-
Placebo3 mg/kg 
Nivolumab-
Placebo
Arm B 
Nivolumab 
+ 
Ipi[INVESTIGATOR_540101]3 mg/kg 
Nivolumab10 mg/kg
Ipi[INVESTIGATOR_125]-
Placebo3 mg/kg 
Nivolumab3 mg/kg 
Nivolumab
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703974] cannot receive a dose within 3 days (or 7 days for dosing visits of Week 24, Week 36 
and Week 48) of its scheduled administration date, the dose sho uld be completely omitted. There 
should be a  minimum of 12 days between 2 nivolumab/nivolumab-pl acebo administrations. When 
the subject is able to re-initiate treatment, dosing should res ume at the time of the next scheduled 
dose. Missed doses will not be replaced. 
4.5.2 Antiemetic Premedications
Antiemetic premedications should not be routinely administered prior to dosing of drugs. See 
Section 4.5.7 for premedication recommendations following a nivolumab or ipil imumab related 
infusion reaction.
4.5.3 Dose Delay Criteria
Dose delays will not be allowed.
4.5.4 Dose Omission Criteria for Nivolumab or Ipi[INVESTIGATOR_489522] (not delayed ) if any of the following criteria 
are met:
‚Ä¢Any Grade 2 non-skin, drug-related adverse event, with the foll owing exceptions:
‚àíGrade 2 drug-related fatigue or l aboratory abnormalities do not  require dose omission
‚àíPlease note that endocrine abnormalities, eg, TSH depression, are not considered isolated 
laboratory abnormalities since they involve symptoms at Grade 2 .  Therefore, endocrine 
adverse events of Grade 2 should lead to dose omission
‚Ä¢Any Grade 3 skin, drug-related adverse event 
‚Ä¢Any Grade [ADDRESS_703975], ALT, or total bilirubin: 
‚àíGrade 3 lymphopenia or leukopenia does not require dose omissio n
‚àíIf a subject has baseline AST, ALT, or total bilirubin that is within normal limits, omit 
dosing for drug-related Grade ‚â•2 toxicity
‚àíIf a subject has baseline AST, ALT, or total bilirubin within t he Grade 1 toxicity range, 
omit dosing for drug-related Grade ‚â•3 toxicity
‚àíGrade 3 amylase or lipase abnor malities that are not associated with symptoms or clinical 
manifestations of pancreatitis do not require a dose omissi on. It is recommended that the 
BMS medical monitor be consulted f or Grade 3 amylase or lipase a bnormalities. 
‚Ä¢Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the investigator, warrants omitting the dose of study medicatio n.
If the criteria to resume treatment (specified in  Section 4.5.6 ) are met within the dosing window 
(Day 1, Week X ¬± 3 days, Week 24, Week 36 and Week 48 ¬± 7 days), th en the dose may be given.
Note: per BMS standards, the term ‚Äúinterruption‚Äù is reserved fo r interruption of the actual IV 
infusion during adminis tration. The terms omission and inte rruption should not be used 
synonymously when completing the CRF forms.
Revised Protocol No: 06
Date: 14-Oct-2020 55
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
[IP_ADDRESS] Adverse Event Management Algorithms for Immuno-Oncology Agents
Immuno-oncology (I-O) agents are associated with adverse events that can differ in severity and 
duration than adverse events caused by [CONTACT_102439] s. Nivolumab and ipi[INVESTIGATOR_482510]-oncology agents in this protocol. Early recog nition and management of 
adverse events associated with immuno-oncology agents may mitigate severe toxicity. 
Management al gorithms have been developed to assist investigato rs in assessing and managing 
the following groups of adverse events: gastrointestinal, renal , pulmonary, hepatic, 
endocrinopathies, skin and neurological. The management algorith ms can be found in Appendix [ADDRESS_703976] dose (which 
includes pneumonitis, diarrhea/coli tis, hepatitis, nephritis/re nal dysfunction, rash, and endocrine 
abnormalities [adrenal insufficiency, hypothyroidism/thyroiditi s, hyperthyroidism, diabetes 
mellitus, and hypophysitis]), regardless of causality, for which  subjects received 
immunosuppressive med ication for treatment of  the event.  The e xception to the 
immunosuppressive medication criteria for IMAEs is endocrine ev ents 
(hypothyroidism/thyroiditis, hype rthyroidism, hypophysitis, dia betes mellitus, adrenal 
insufficiency), which are included regardless of treatment sinc e these events are often managed 
without immunosuppression.
4.5.5 Dose Modifications
Dose reductions or dose escalations are not permitted.
All dose modificatio n rules apply to both arms given the blinded  nature of this study.
4.5.6 Criteria to Resume Treatment
All criteria to resume treatm ent for nivoluma b and ipi[INVESTIGATOR_125] a lso apply for the placebo version 
of each agent, given the blinded nature of this study.
Subjects may resume treatment with study drug when the drug-related AE(s) resolve to Grade ‚â§1 
or baseline value, with the following exceptions:
‚Ä¢Subjects may resume treatment in the presence of Grade 2 fatigu e 
‚Ä¢Subjects who have not experienced a Grade 3 drug-r elated skin AE may res ume treatment in 
the presence of Grade 2 skin toxicity 
Revised Protocol No: 06
Date: 14-Oct-2020 56
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚Ä¢Subjects with baseline Grade [ADDRESS_703977]/ALT or total bilirubin who r equire dose omissions for 
reasons other than a 2-grade s hift in AST/ALT  or total  bilirubi n may resume treatment in the 
presence of Grade [ADDRESS_703978]/ALT OR Grade 2 total bilirubin
‚Ä¢Subjects with combined Grade [ADDRESS_703979]/ALT AND tota l bilirubin valu es meeting 
discontinuation parameters ( Section 4.5.5 ) should have treatment permanently discontinued
‚Ä¢Drug-related pulmonary toxicity , diarrhea, colitis, uveitis or neurological toxicity, must have 
resolved to baseline before treatment is resumed
‚Ä¢Drug-related endocrinopathies adequately controlled with only p hysiologic hormone 
replacement may resume treatment.
If the cr iteria to resume treatment are met, the subject should restart treatment at the next scheduled 
timepoint per protocol. However, if the tr eatment is withheld past the wi ndow period of the next 
scheduled timepoint per protocol to ensure adequ ate recovery from the adverse event or tapering 
of immunosuppression, the dosing should continue to be withheld  until the subsequent scheduled 
timepoint. 
If treatment is withheld > [ADDRESS_703980] be permanently discontinued 
from study therapy, except as specified in Section  4.5.7.
4.5.7 Discontinuation Criteria
All discontinuation criteria for nivolumab and ipi[INVESTIGATOR_540102], given the blinded nature of this study.
Treatment should be permanently discontinued for the following:
‚Ä¢Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not respond to topi[INVESTIGATOR_61780] 1 severity within  3 week s OR requires systemic 
treatment 
‚Ä¢Any Grade 3 non-skin, drug-related adverse event lasting > 7 da ys, with the following 
exceptions for drug-r elated labor atory abnorm alities, uveitis, pneumonitis, bronchospasm, 
diarrhea, colitis, neurologic toxicity, hypersensitivity reacti ons, and infusion reactions:
‚àíGrade 3 drug-related uveitis, pneumonitis, bronchospasm, diarrh ea, colitis, neurologic 
toxicity, hypersensitivity reaction, or infusion reaction of an y duration requires 
discontinuation
‚àíGrade 3 drug-related laboratory a bnormalities do not require treatment discontinuation 
except: 
‚ô¶Grade 3 drug-related thrombocytopenia > 7 days or associated wi th bleeding requires 
discontinuation
‚ô¶Any drug-related liver function test (LFT) abnormality that mee ts the following criteria 
require discontinuation: 
oAST or ALT > [ADDRESS_703981]
oTotal bilirubin > [ADDRESS_703982] or ALT > [ADDRESS_703983] and total bilirubin > [ADDRESS_703984]
Revised Protocol No: 06
Date: 14-Oct-2020 57
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚Ä¢Creatinine greater than [ADDRESS_703985]
‚Ä¢Any severe or Grade 3 immune-mediated adverse reaction that rec urs on reintroduction of 
nivolumab or ipi[INVESTIGATOR_125], or an ina bility to redu ce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks
‚Ä¢Persistent Grade [ADDRESS_703986] dose of study drug
‚Ä¢Any Grade 4 drug-related adverse event or la boratory abnormalit y, except for the following 
events which do not require discontinuation:
‚àíGrade 4 amylase or lipase abnor malities that are not associated with symptoms or clinical 
manifestations of pancreatitis. It is recommended to consult wi th the BMS Medical 
Monitor for Grade 4 amylase or lipase abnormalities.
‚àíIsolated Grade 4 electroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management with in 72 hours 
of their onset
‚Ä¢Dosing that is withheld > [ADDRESS_703987] dose with the f ollowing exceptions:
‚àíDosing omissions to allow for prolonge d steroid tapers to manage drug-related adverse 
events are allowed. Prior to re-initiating treatment in a subje ct with a dosing omission 
period lasting >  [ADDRESS_703988] be consulted. 
‚àíDosing omissions > [ADDRESS_703989] with a dosing omission period lasting > [ADDRESS_703990] be consulted. 
‚Ä¢Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of 
the Investigator, presents a substantial clinical risk to the s ubject with continued nivolumab or 
ipi[INVESTIGATOR_45770].
‚Ä¢Tumor surveillance assessments, Qo L questionnaires  collection a nd biomarker sampling
should continue as per protocol even if dosing is omitted.
4.5.[ADDRESS_703991] with fever, chills, r igors, headache, rash, pruritis, 
arthralgias, hypo- or hypertension, bronchospasm, o r other symptoms. All Grade 3 or 4 i nfusion 
reactions should be reported within 24 hours to the BMS Medical  Monitor and reported as an SAE 
if criteria are met. Infusion r eactions should be graded according to National Cancer Institut e 
Common Terminology Criteria for Adverse Events (NCI CTCAE  (version 4.0)) guidelines.
Treatment recommendations are provided below and may be modifie d based on local treatment 
standards and guidelines as appropriate:
For Grade 1 symptoms : (Mild reaction; infusion inte rruption not ind icated; intervention not 
indicated)
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703992] until recovery from sympt oms. The following prophylactic 
premedications are recommended for future infusions: diphenhydr amine 50 mg (or equivalent) 
and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 mi nutes before additional 
nivolumab or ipi[INVESTIGATOR_45782].
For Grade 2 symptoms : (Moderate reaction requires therapy or i nfusion inte rrupti on but responds 
promptly to symptomatic treatment [eg, antihis tamines, non-steroidal anti-inf lammatory drugs, 
narcotics, corticosteroids, bronchodilators, IV fluids]; prophy lactic medications indicated for ‚â§24 
hours).
Stop the nivolumab or ipi[INVESTIGATOR_125] i nfusion, begin an IV infusion  of normal saline, and treat the 
subject with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until re solution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administer ed as appropriate. If the i nfusion 
is interrupted, then restart the infusion at 50% of the original infusion rate when symptoms resolve; 
if no further complications ensue after 30 minutes, the rate may  be increased to 100% of the 
original infusion rate. Monitor subject closely. If symptoms recur then no further nivolumab or 
ipi[INVESTIGATOR_114569]. Administer diphe nhydramine [ADDRESS_703993] be recorded on the electronic case report form (eCRF). The  following prophylactic 
premedications are recommended for future infusions: diphenhydr amine 50 mg (or equivalent) 
and/or paracetamol 325 t o 1000 mg ( acetaminophen) should be admin istered at least 30 minutes 
before additional nivolumab or ipi[INVESTIGATOR_45782]. If n ecessary, corticosteroids 
(recommended dose: up to 25 mg of IV hydrocortisone or equivalen t) may be used.
For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not rapi[INVESTIGATOR_441803]/or brief interruption of infusion]; recurrence of 
symptoms following initial improvement; hospi[INVESTIGATOR_327620] [eg, 
renal impairment, pulmonary infiltrates]). Grade 4: (life-threa tening; pressor or ventilat ory support 
indicated). 
Immediately discontinue infusion of nivolumab or ipi[INVESTIGATOR_125]. Be gin an IV infusion of normal 
saline, and treat the subject as follows. Recommend bronchodila tors, epi[INVESTIGATOR_238] 0.2 to 1 mg of a 
1:1,000 solution for subcutaneous administration or 0.1 to 0.25  mg of a 1:10,000 solution injected 
slowly for IV administration, and/or diphenhydramine 50 mg IV wi th methylprednisolone 100 mg 
IV (or equivalent), as needed. Subject should be monitored unti l the investigator is comfortable 
that the symptoms will not recur. Nivolumab or ipi[INVESTIGATOR_102341]. 
Investigators should follow their institutional guidelines for t he treatment of anaphylaxis. Remain 
at bedside and monitor subject until recovery from symptoms. In  the case of late-occurring 
hypersensitivity symptoms (eg, appearance of a localized or gen eralized pruritis within 1 week 
after treatment), symptomatic treatment may be given (eg, oral a ntihistamine, or corticosteroids).
4.6 Blinding/Unblinding
Blinding of treatment assignment is critical to the integrity o f this clinical study. The management 
of adverse events for either nivolumab or ipi[INVESTIGATOR_540103] e, according to the harmonized 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703994]'s management, 
the blind for that subject may be broken by [CONTACT_093]. The subject‚Äôs safety takes priority 
over any other considerations in determining if a treatment ass ignment should be unblinded.
Before breaking the blind of an individual subject's treatment,  the investigator should determine 
that the unblinded information is necessary, ie, that it w ill alter the  subject's immediate 
management. In many cases, particularly when the emergency is c learly not related to the 
investigation al product, the  problem may be properly managed by  [CONTACT_82745]. It is highly desirable that the decis ion to unblind treatment assignment 
be discussed with the Medical Monitor, but the i nvestigator alw ays has ultimate authority for the 
decision to unblind. 
Any request to unblind a subject for non-emergency purposes sho uld be discussed with the 
Medical Monitor. For example, for subjects that have recurrence and discontinue treatment the 
investigator may require knowledge of which treatment arm they were assigned to in order to 
appropriately select any post-recurrence subsequent therapy. Se e Section [IP_ADDRESS] .
For this study, the method of unblinding is IVRS.The Principal Investigator [CONTACT_210068] d only call in for unblinding A FTER the decision to discontinue 
the subject has been made.
For information on how to unblind for emergency, please consult  the IVRS manual.
In cases of accidental unblinding, contact [CONTACT_122382].
In addition, designated staff o f [COMPANY_016] Company ma y be unblinded prio r to database 
lock to facilitate the bi oanalytical analysi s of pharmacokineti c samples and immunogenicity. A 
bioanalytical scientist in the Bioanalytical Sciences departmen t of [COMPANY_016] Company
(or a designee in the external cen tral bioanalytical laboratory ) will be unblinded to the randomized 
treatment assignments in order to minimize unnecessary bioanaly tical analysis of samples.
To further minimize bias, the sponsor central study team and the investigative clinical site staff are 
blinded to results from PD-L1 analysis.
4.[ADDRESS_703995]‚Äôs medical 
record and eCRF.
4.8 Destruction of Study Drug
For this study, study drugs (those supplied by [CONTACT_20456] b y the investigator) such as partially 
used study drug containers, vials and syringes may be destroyed  on site. 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_703996] be immediately destroyed as required 
for safety, or to meet local regulations (eg, cytotoxics or bio logics). 
On-site destruction is allowed provided the following minimal s tandards are met:
‚Ä¢On-site disposal practices must not expose humans to risks from  the drug.
‚Ä¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
‚Ä¢Written procedures for on-site disposal are available and follo wed. The procedures must be 
filed with the site‚Äôs standard operating procedures (SOPs) and a copy  provided t o BMS upon 
request.
‚Ä¢Records are maintain ed that allow for traceability of each cont ainer, including the date 
disposed of, quantity disposed, and identif ication of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
‚Ä¢Accountability and disposal records are complete, up-to-date, a nd available for the Monitor to 
review throughout the clinical trial period.
If conditions for destruction cannot be met the responsible Stu dy Monitor will make arrangements 
for return of study drug.
It is the investigator‚Äôs responsibility to arrange for disposal  of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.4.9 Return of Study Drug
If study drug will not be destroyed upon completion or terminati on of the study, all unused and/or 
partially used st udy drug that was supplied by [CONTACT_61870]. The return of study 
drug will be arranged by [CONTACT_20459]. 
It is the investigator‚Äôs res ponsibility to arrange for disposal  of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept. 
Revised Protocol No: 06
Date: 14-Oct-2020 61
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
5 STUDY ASSESSMENTS AND PROCEDURES
5.1 Flow Chart/Time and Events Schedule 
Table 5.1-1: Screening Procedural Outline (CA209238)
ProcedureScreening
Visit
(Day -28 till Day -1 prior to 
Randomization)Notes
Eligibility Assessments
Informed Consent x
Inclusion/Exclusion Criteria xAll inclusion/exclusion criteria should be assessed during screening 
and confirmed prior to randomization.
Medical History x
Review of pathology report xStage III: The pathology report must be reviewed, signed and dated by 
[CONTACT_98653].
Stage IV: The pathology report confirming negative margins must be 
reviewed, dated, and signed by [CONTACT_540125].
 
 
Safety Assessments
Physical Examination x Including height
Vital Signs x Including weight, blood pressure (BP), heart rate (HR), temperature 
Oxygen saturation x By [CONTACT_540126] (ECOG) x Within 14 days prior to randomization
Assessment of Signs and Symptoms x Within 14 days prior to random ization
Electrocardiogram (ECG) x Within 14 days prior to randomization
Revised Protocol No: 06
Date: 14-Oct-2020 62
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-1: Screening Procedural Outline (CA209238)
ProcedureScreening
Visit
(Day -28 till Day -1 prior to 
Randomization)Notes
Laboratory Tests xOn site/local complete blood count (CBC) w/differential, Chemis try 
panel including: LDH, AST, ALT, ALP, T.Bili, amylase, lipase, b lood 
urea nitrogen (BUN) or serum urea level, creatinine, Ca, Mg, Na , K, 
Cl, Glucose, endocrine panel (TSH, Free T4, Free T3) within 14 days 
prior to randomization.
Hep B/C (HBV sAG, HCV antibody or HCV RNA) within [ADDRESS_703997], abdomen, pelvis and all known sites of res ected 
disease in the setting of Stage IIIb/c and Stage IV and brain MR I (brain 
CT allowable if MRI is contraindicated or if there is no known h istory 
of resected brain lesions).
Other
IVRS call x
Revised Protocol No: 06
Date: 14-Oct-2020 63
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-2: On-Treatment Assessments Week 1 - Week 9 (CA209238)
Procedure Day [ADDRESS_703998] and after exertion 
prior to dosing
Weight and performance status x x x x x x Within 72 hours prior to dosi ng
Adverse Events Assessment Continuously
Laboratory Tests x x x Within 72 hrs prior to dosing to include CBC 
w/differential, AST, ALT, ALP, T. Bili, BUN 
or serum urea level, creatinine, Ca, Mg, Na, K, 
Cl, LDH, Glucose, amylase, lipase, TSH (with 
reflexive Free T4 and Free T3)
Note: Laboratory tests do not need to be 
repeated if performed within [ADDRESS_703999] x x x Within 24 hours prior to the initial 
administration of study drug, then every 
4 weeks ¬±1 week. Serum or Urine
 
 
Revised Protocol No: 06
Date: 14-Oct-2020 64
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-2: On-Treatment Assessments Week 1 - Week 9 (CA209238)
Procedure Day 1 
Week 1Day 1 
Week 3Day 1 
Week 4Day 1 
Week 5Day 1 
Week 7Day 1 
Week 9Notes
 
 
 
 
Efficacy Assessments
Surveillance AssessmentsEvery 12 weeks ( ¬±7 days) from first dose of study treatment 
through 12 months (until local, regional, or distant recurrence  
[whichever comes first] for Stag e IV subjects and until distant 
recurrence for Stage III subjects)CT scan neck, chest, abdomen, pelvis and all 
known sites of resected disease in the setting of 
Stage IIIb/c and Stage IV and brain MRI (brain 
CT allowable if MRI is contraindicated or if 
there is no known history of resected brain 
lesions). Use same imaging method as was 
used at screening/baseline.
Revised Protocol No: 06
Date: 14-Oct-2020 65
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-2: On-Treatment Assessments Week 1 - Week 9 (CA209238)
Procedure Day 1 
Week 1Day 1 
Week 3Day 1 
Week 4Day 1 
Week 5Day 1 
Week 7Day 1 
Week 9Notes
Study Drug
IVRS Randomize x
Dispense Study Treatment (Active 
drug or p lacebo - blinded)xxxxxxFirst dose to be administered within 3 business
days of randomization. See Section 4.3 . 
Subsequent doses may be administered within 
3 days before or after the scheduled date if 
necessary.
Outcome Research Assessments
EORTC-QLQ-C30 x x x
Prior to dosing. D1W1 should be completed 
after randomization but prior to dosing.
Revised Protocol No: 06
Date: 14-Oct-2020 66
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-3: On-Treatment Assessments Week 10 - Week 19 (CA209238 )
ProcedureDay [ADDRESS_704000] and after exertion 
prior to dosing
Weight and performance status x x x x x x Within 72 hours prior to dosi ng
Adverse Events Assessment Continuously
Laboratory Testsxx Within 72 hrs prior to dosing to include CBC 
w/differential, AST, ALT, ALP, T. Bili, BUN or 
serum urea level, creatinine, Ca, Mg, Na, K, Cl, 
LDH, Glucose, amylase, lipase, TSH (with 
reflexive Free T4 and Free T3)
Pregnancy Test xx Every 4 weeks ¬±1 week. Serum or Urine
 
 
  
 
Revised Protocol No: 06
Date: 14-Oct-2020 67
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-3: On-Treatment Assessments Week 10 - Week 19 (CA209238 )
ProcedureDay 1 
Week 10Day 1 
Week 
11Day 1 
Week 
13Day 1 
Week 
15Day 1 
Week 
17Day 1 
Week 
19Notes
 
 
  
Efficacy Assessments
Surveillance AssessmentsEvery 12 weeks ( ¬±7 days) from first dose of study treatment 
through 12 months (until local, regional, or distant recurrence  
[whichever comes first] for Stage IV subjects; until distant 
recurrence for Stage III subjects)CT scan neck, chest, abdomen, pelvis and all 
known sites of resected disease in the setting of 
Stage IIIb/c and Stage IV and brain MRI (brain 
CT allowable if MRI is contraindicated or if 
there is no known history of resected brain 
lesions). Use same imaging method as was used 
at screening/baseline.
Study Drug
Dispense Study Treatment (Active drug or p lacebo - blinded)xxxxxx See Section 4.3 . Subsequent doses may be 
administered within 3 days before or after the 
scheduled date if necessary.
Outcome Research Assessments
EORTC-QLQ-C30 x x
Prior to dosing
Revised Protocol No: 06
Date: 14-Oct-2020 68
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-4: On-Treatment Assessments Week 21 - Week 29 (CA209238 )
ProcedureDay [ADDRESS_704001] and after exertion prior 
to dosing
Adverse Events Assessment Continuously
Laboratory Tests x x xWithin 72 hrs prior to dosing to include CBC 
w/differential, AST, ALT, ALP, T. Bili, BUN or 
serum urea level, creatinine, Ca, Mg, Na, K, Cl, 
LDH, Glucose, amylase, lipase, TSH (with 
reflexive Free T4 and Free T3)
Pregnancy Test x x x Every 4 weeks ¬± 1 week. Serum or Urine
 
 
Revised Protocol No: 06
Date: 14-Oct-2020 69
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-4: On-Treatment Assessments Week 21 - Week 29 (CA209238 )
ProcedureDay 1 
Week 
21Day 1 
Week 
23Day 1 
Week 
24Day 1 
Week 
25Day 1 
Week 
27Day 1 
Week 
29Notes
 
  
Efficacy Assessments
Surveillance AssessmentsEvery 12 weeks ( ¬±7 days) from first dose of study treatment 
through 12 months (until local, regional, or distant recurrence  
[whichever comes first] for Stage IV subjects and until distant 
recurrence for Stage III subjects)CT scan neck, chest, abdomen, pelvis and all 
known sites of resected disease in the setting of 
Stage IIIb/c and Stage IV and brain MRI (brain 
CT allowable if MRI is contraindicated or if 
there is no known history of resected brain 
lesions). Use same imaging method as was used 
at screening/baseline.
Study Drug
Dispense Study Treatment (Active 
drug or p lacebo - blinded)xxxxxxSee Section 4.3 . Subsequent doses may be 
administered within  3 days (7 days for Week 24)
before or after the scheduled date if necessary
Outcome Research Assessments
EORTC-QLQ-C30 x
Prior to dosing
Revised Protocol No: 06
Date: 14-Oct-2020 70
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-5: On-Treatment Assessments Week 31 - Week 39 (CA209238 )
Procedure Day [ADDRESS_704002] and after exertion prior 
to dosing
Weight and performance status x x x x x x Within 72 hours prior to dosing
Adverse Events Assessment Continuously
Laboratory Testsxx Within 72 hrs prior to dosing to include CBC 
w/differential, AST, ALT, ALP, T. Bili, BUN or 
serum urea level, creatinine, Ca, Mg, Na, K, Cl, 
LDH, Glucose, amylase, lipase, TSH (with 
reflexive Free T4 and Free T3)
Pregnancy Test xx Every 4 weeks ¬±1 week. Serum or Urine
 
 
Revised Protocol No: 06
Date: 14-Oct-2020 71
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-5: On-Treatment Assessments Week 31 - Week 39 (CA209238 )
Procedure Day 1 
Week 
31Day 1 
Week 
33Day 1 
Week 
35Day 1 
Week 
36Day 1 
Week 
37Day 1 
Week 
39Notes
 
 
Efficacy Assessments
Surveillance AssessmentsEvery 12 weeks ( ¬±7 days) from first dose of study treatment 
through 12 months (until local, regional, or distant recurrence  
[whichever comes first] for Stage IV subjects and until distant 
recurrence for Stage III subjects)CT scan neck, chest, abdomen, pelvis and all 
known sites of resected disease in the setting of 
Stage IIIb/c and Stage IV, and brain MRI (brain 
CT allowable if MRI is contraindicated or if 
there is no known history of resected brain 
lesions). Use same imaging method as was used 
at screening/baseline.
Study Drug
Dispense Study Treatment (Active 
drug or p lacebo - blinded)xxxxxxSee Section 4.3 . Subsequent doses may be 
administered within 3 days (7 days for Week 36) 
before or after the scheduled date if necessary.
Outcome Research Assessments
EORTC-QLQ-C30 x
Prior to dosing
Revised Protocol No: 06
Date: 14-Oct-2020 72
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-6: On-Treatment Assessments Week 41 - Week 51 (CA209238 )
ProcedureDay [ADDRESS_704003] and after exertion prior 
to dosing
Adverse Events Assessment Continuously
 x x xxx
Laboratory Tests x x xWithin 72 hrs prior to dosing to include CBC 
w/differential, AST, ALT, ALP, T. Bili, BUN or 
serum urea level, creatinine, Ca, Mg, Na, K, Cl, 
LDH, Glucose, amylase, lipase, TSH (with 
reflexive Free T4 and Free T3)
ACTH at Week 45 in subjects receiving 
ipi[INVESTIGATOR_125]/ ipi[INVESTIGATOR_125]-placebo at Week 48
(note that all subjects will have completed 36
weeks at the time of implementation)
Pregnancy Test x x x Every 4 weeks ¬± 1 week. Serum or Urine.
 
 
Revised Protocol No: 06
Date: 14-Oct-2020 73
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-6: On-Treatment Assessments Week 41 - Week 51 (CA209238 )
ProcedureDay 1 
Week 
41Day 1 
Week 
43Day 1 
Week 
45Day 1 
Week 
47Day 1 
Week 
48Day 1 
Week 
49Day 1 
Week 
51Notes
 
  
 
 
Efficacy Assessments
Surveillance AssessmentsEvery 12 weeks ( ¬±7 days) from first dose of study 
treatment through 12 months (until local, regional, or 
distant recurrence [whichever comes first] for Stage IV
subjects and until distant recurrence for Stage III subjects)CT scan neck, chest, abdomen, pelvis and all 
known sites of resected disease in the setting of 
Stage IIIb/c and Stage IV and brain MRI (brain 
CT allowable if MRI is contraindicated or if there 
is no known history of resected brain lesions). 
Use same imaging method as was used at 
screening/baseline.
Study Drug
Dispense Study Treatment 
(Active drug or placebo - blinded)x xxxxxx See Section 4.3 . Subsequent doses may be 
administered within 3 days (7 days for Week 48)
before or after the scheduled date if necessary.
Note: As of Dec-2016, all subjects in both 
treatment groups were off study treatment.
Outcome Research Assessments
EORTC-QLQ-C30 x
Prior to dosing
Revised Protocol No: 06
Date: 14-Oct-2020 74
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-6: On-Treatment Assessments Week 41 - Week 51 (CA209238 )
ProcedureDay 1 
Week 
41Day 1 
Week 
43Day 1 
Week 
45Day 1 
Week 
47Day 1 
Week 
48Day 1 
Week 
49Day 1 
Week 
51Notes
Revised Protocol No: 06
Date: 14-Oct-2020 75
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-7: Follow-Up Procedural Outline (CA209238)
Procedure Follow-up, 
Visits 1 and 2aSurvival, Follow up Visitsb Notes
Safety Assessments
Targeted Physical Examination x
Adverse Events Assessment x x See Section 6.2.1 .Immune-mediated adverse reactions should 
be followed until stabilization.
Nonimmune-mediated adverse reactions should be followed 
until resolution or stabilization.
Laboratory Tests x Laboratory toxicities (eg, suspected drug induced liver enzyme 
elevations) will be monitored duri ng the follow-up phase, based 
on results from on-site/local labs, until all study drug related 
toxicities resolve, return to baseline, or are deemed irreversi ble.
Pregnancy Test x Serum or urine
 
Outcome Research Assessments
EORTC-QLQ-C30 x
 
Revised Protocol No: 06
Date: 14-Oct-2020 76
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-7: Follow-Up Procedural Outline (CA209238)
Procedure Follow-up, 
Visits 1 and 2aSurvival, Follow up Visitsb Notes
Efficacy Assessments
Surveillance Assessment‚Ä¢Every 12 weeks ( ¬±7 days) < 12 months
‚Ä¢Every 12 weeks ( ¬±14 days) > 12 months 
through 24 months
‚Ä¢Every 6 months ( ¬±4 weeks) > 24 months 
through and up to Year 5
Until local, regional, or distant recurrence (whichever comes first) for Stage IVsubjects and until distant recurrence for Stage III subjects.All time points are relative to the first dose of study treatment.CT scan neck, chest, abdomen, pelvis and all known sites of 
resected disease in the setting of Stage IIIb/c and Stage IV an d 
brain MRI (brain CT allowable if MRI is contraindicated or if 
there is no known history of resected brain lesions). Use same 
imaging method as was used at screening/baseline.
Note: If a subject starts systemic therapy for melanoma 
recurrence after study drug discontinuation, follow-up scans 
should be discontinued. If a subject starts systemic therapy fo r a 
new non-melanoma tumor after study drug discontinuation, 
follow-up scans can be done as per standard of care.
Effective Revised Protocol 06: Although study-specified
surveillance assessments will not be conducted beyond Year 5, 
data on recurrence of melanoma (loco-regional and distant), as 
well as development of new primary melanomas and non-
melanoma cancers will continue to be collected in the respectiv e 
Case Report Forms. Subjects will be queried for this data during  
the routine survival status follow-up. This data will also be 
collected retrospectively to account for any time interval 
between the subject's Year 5 time point and approval of Revised  
Protocol 06 by [CONTACT_39989]/IRBs.
Survival status
Survival status x x Every 3 months (¬± 14 days), maybe acco mplished by [CONTACT_219090],cto include subsequent anti-cancer therapy. The 
frequency and mode of contact [CONTACT_540127]-up  
period as well. This data will be collected retrospectively to 
Revised Protocol No: 06
Date: 14-Oct-2020 77
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Table 5.1-7: Follow-Up Procedural Outline (CA209238)
Procedure Follow-up, 
Visits [ADDRESS_704004]'s Year 5 time  
point and approval of Revised P rotocol 06 by  [CONTACT_39989]/IRBs.
 
  
 
 
  
  
aFollow-up visit 1 (FU1) = 30 days ( ¬±7 days) from the last dose or coincide with the date of discontinuation ( ¬±7days) if date of discontinuation is greater than 
[ADDRESS_704005] dose, Follow-up visit 2 (FU2) = 84 days ( ¬±7 days) from follow-up visit [ADDRESS_704006] Survival Follow-up visit 3 months (¬± 14 days) after FU2
cPhone contacts during the survival follow-up visits are only al lowed at time periods between surveillance assessment visits.
Revised Protocol No: 06
Date: 14-Oct-2020 78
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
5.1.1 Retesting During Screening or Lead-in Period
Retesting of laboratory paramet ers and/or other assessments wit hin any single Screening will be 
permitted (in addition to any parameters that require a confirm atory value).
Any new result will override the previous result (ie, the most current result prior to Randomization) 
and is the value by [CONTACT_109419], as it represents the subject‚Äôs most 
current, clinical state. 
Laboratory parameters and/or assessments that are included in  Table 5.1-1 , Screening Procedural 
Outline may be repeated in an effort to find all possible well- qualified subjects. Consultation with 
the Medical Monitor may be needed to identify whether repeat te sting of any particular parameter 
is clinically relevant.5.2 Study Materials
‚Ä¢NCI CTCAE version 4.0
‚Ä¢Nivolumab Investigator Brochure
‚Ä¢Ipi[INVESTIGATOR_121002]
‚Ä¢Pharmacy binder
‚Ä¢Laboratory manuals for collection and handling of blood (includ ing biomarker and 
immunogenicity) and tissue specimens
‚Ä¢Site manual for operation of IVRS , including enrollment/randomization worksheets
‚Ä¢Manual for entry of local laboratory data
‚Ä¢Pregnancy Surveillance Forms
‚Ä¢PRO instruments.
5.[ADDRESS_704007] and  after exertion and should be 
performed as noted in  Table 5.1-1 Notes. Baseline signs and symptoms are those that are assessed 
within 14 days prior to randomization. Concomitant medications will be collected from within 
14 days prior to randomization through the study treatment perio d and follow-up visits 1 and 2. 
(See Tables from Section 5.1 .) During the Survival Follow-up visits subsequent only anti-can cer 
therapy will be collected.
Baseline local laboratory assessments should be done within 14 days prior to randomization to 
include: CBC w/differential, LFTs (ALT, AST, total bilirubin, a lkaline phosphatase), BUN or 
serum urea level, creatinine, Ca, Mg, Na, K, Cl, LDH, glucose, amylase, lipase, TSH, Free T4, 
Free T3; Hep B and C testing (HBV sAg, HCV RNA, HCV antibodies) s hould be assessed within 
28 days prior t o randomization (Table 5.1-1 ). Pregnancy testing for WOCBP (done locally) must 
be performed wit hin 24 hours prior to the ini tial administration  of study drug at baseline and then 
every 4 weeks ( ¬±1 week) during the treatment phase. 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704008] r eceived any study drug. Toxicity assessments 
will be continuous during the tr eatment phase. During the safety follow-up phase Table 5.1-7 , 
toxicity assessments should be done in person. Once subjects re ach the survival follow-up phase 
either in person or documented telephone calls (telephone calls  are only allowed during times 
where no surveillance assessments are to be done) to assess the subject‚Äôs status are acceptable. 
Adverse events and laboratory values will be graded according t o the NCI CTCAE version 4.0.
On-study weight and ECOG Performance status and vital signs sho uld be assessed on at each 
on-study visit .Vital signs should also be taken as per institu tional standard of care prior to, during 
and after dosing. Oxygen saturation by [CONTACT_540128] d after exertion should be assessed 
at each on study visit pri or to dosing. The start and stop time of the blinded infusions s hould be 
documented. Physical ex aminations are to be performed as clinically indicated. If ther e are any 
new or worsening clinically significant changes since the last exam, report changes on the 
appropriate non-serious or serious adverse event page.On study local laboratory assessments should be done within 72 hours prior to dosing (laboratory 
tests should not be repeated if performed within [ADDRESS_704009] dose) to include; CBC 
w/differential, LFTs (ALT, AST, total bilirubin, alkaline phosp hatase), BUN or serum urea level, 
creatinine, Ca, Mg, Na, K, Cl, LDH, glucose, amylase, lipase, T SH with reflexive Free T4, 
Free T3. Adrenocorticotropic hormone (ACTH) w ill be assessed at Week 45 prior to 
ipi[INVESTIGATOR_125]/ ipi[INVESTIGATOR_540104] 48, since a ll subjects  will be past the 
36 weeks‚Äô timepoint. Additional measures including non-study requ ired laboratory tests should be 
performed as clinically indicated or to comply with local regul ations. Laboratory toxicities (eg, 
suspected drug inducted liver enz yme elevations) will be monito red during the follow-up phase 
via on site/local labs  until all study drug related toxicities resolve, return to base line or are deemed 
irreversible. Oxygen saturation by [CONTACT_540129] a 
subject has any new or worsening respi[INVESTIGATOR_1856]. Accur ate recording and documen tation 
of oxygen saturation at two different activity levels is import ant because drug-related pulmonary 
toxicity can present initially as lower than baseline oxygen sa turation.  A reading at rest and on 
exertion should be obtained at each time point. The extent of th e exertion should be based on the 
judgment of the investigator, but should remain consistent for each individual subject throughout 
the study. If the  subject‚Äôs status changes, the investigator ca n alter the extent of exertion based on 
their medical j udgment. If a subject shows changes on pulse oximetry or other pulmonary related 
signs (hypoxia, fever) or sympto ms (eg, dyspnea, cough, fever) consistent with possible pulmonary 
adverse events, the subject should be immed iately evaluated to r ule out pulmonary toxicity. An 
algorithm f or the management of suspecte d pulmonary toxicity can be found in Appendix 4 or the 
nivolumab investigator brochure.Some of the previously referred to assessments may not be captu red as data in the eCRF. They are 
intended to be used as safety monitoring by [CONTACT_448311]. Additional testing or 
assessments may be performed as clinically necessary  or where required by [CONTACT_540130].
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704010] medical/clinical judgment.
5.[ADDRESS_704011], abdomen, pelvis and all known sites of resected disease in the 
setting of Stage IIIb/c and Stage IV, and brain MRI (brain CT a llowable if MRI is contraindicated 
or if there is no known history of resected brain lesions). Subj ects will be evalu ated for presence 
or continued lack of tumor until local, regional , or distant rec urrence (whichever comes first) for 
Stage IV subjects and until distant recurrence for Stage III su bjects beginning 12 weeks ( ¬±7 days) 
relative to the first dose of study treatment, and will continu e to have surveillance assessment every 
12 weeks ( ¬±7 days) for the first 12 months. From > 12 months to 24 months af ter randomization, 
efficacy assessments should be every 12 weeks (¬± 14 days). From > [ADDRESS_704012] dose of study treatment, efficacy assessments should be p erformed every 6 months ( ¬±4 
weeks).  
If a subject starts systemic therapy for melanoma recurrence af ter study drug discontinuation, 
follow-up scans should be discontinued. If a subject starts syst emic therapy for a new non-
melanoma tumor after study dr ug discontinuati on, follo w-up scan s can be done as per standard of 
care.
5.4.1 Definitions 
Recurrence is defined as the appearance of one or more new mela noma lesions, which can be local, 
regional, or distant in location from t he primary resected site .  
Local Cutaneous Recurrence :
Local cutaneous recurrence after adequate excision of the primary melanoma is associated with 
aggressive tumor biologic features and is frequently a harbinger of metastases.
Regional Lymphatic and Nodal Recurrences:
The neoplastic nature of the re gional recurren ces should be att empted and confirmed by 
[CONTACT_27183]/cytology.
Revised Protocol No: 06
Date: 14-Oct-2020 81
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚Ä¢In Transit Metastases: In transit metastases represents the cli nical manifestations of small 
tumor emboli trapped within the dermis and subdermal lymphatics  between the site of the 
primary tumor and the regional lymph node drainage basin(s).  I n extremities, in transit 
metastases can also occur distal to the site of the primary lesion as a result of reversed 
lymphatic flow.  In transit metastases occur in 10% to 15% in p atients with Stage III disease.  
Although previous staging systems distinguished between the sma ll satellitosis (within 2 cm 
of the primary tum or), pat hophysiologically these two events represent different points o n a 
continuum of the same biologic process.  When present, in transit metastases are usually 
multiple, evolve over time, and, as previously stated, are ofte n the harbinger of subsequent 
systemic disease.
‚Ä¢Regional Node Recurrences: Regional node failure in a previousl y dissected basin is usually 
found at the periphery of the prior surgical procedure.
Patterns of Metastases:
Melanoma is well known for its ability to metastasize to virtua lly any organ or tissue.  The most 
common initial sites of distance metastases are the non-viscera l (skin, subcutaneous tissue, and 
lymph nodes), which are recurrence sites for 42% to 59% of subj ects in various studies.  Visceral 
locations are the lung, brain, liver, gastrointestinal tract, a nd bone; the visceral sites are the initial 
sites of relapse in approximately 25% of all melanoma patients who experience recurrence.
Measurable Disease per RECIST 1.1:
Measurable lesions must be accurately measured in at least one dimension (longest diameter in the 
plane of the measurement to be recorded) with a minimum size of :
‚Ä¢[ADDRESS_704013]/MRI scan - (CT/MRI scan slice thickness no greater th an 5 mm)
‚Ä¢10 mm caliper measurement by [CONTACT_12148] (lesions whic h cannot be accurately 
measured with calipers should be recorded as non-measurable)
‚Ä¢[ADDRESS_704014] x-ray.
Malignant lymph nodes: to be cons idered pathologically enlarged  and measurable per 
RECIST 1.1, a lymph node must be ‚â•[ADDRESS_704015] scan (CT scan 
slice thickness recommended to be no greater than 5 mm).  
If the measurable disease is res tricted to a solitary lesion (v isceral or nodal), its neoplastic nature 
must be confirmed either by [CONTACT_3973]/histology or by [CONTACT_540131]/MRI examination.
Nonmeasurable Disease per RECIST 1.1:
Nonmeasurable lesions include all other lesions, including smal l lesions (l ongest d iameter 
< 10 mm or pathological lymph nodes with ‚â•10 and < 15 mm short axis), as well as truly 
nonmeasurable lesions.  Lesions considered truly nonmeasurable include: leptomeningeal disease, 
ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic involvement of 
Revised Protocol No: 06
Date: 14-Oct-2020 82
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
skin or lung, and abdominal masses/abdominal organomegaly ident ified by [CONTACT_236942].
Note:
‚Ä¢Cutaneous relapses occurring beyond the periphery of the previo us surgical bed (ie, over 2 cm) 
are considered distant metastases.
‚Ä¢Node relapses occurring beyond the anatomical compartment of th e dissected basins are 
considered distant metastases.
‚Ä¢Node relapses in nodal basins situated in a different anato mical compartment or beyond the 
previously dissected basin or in two nodal basins (even if cont iguous; ie, 2 pelvic nodal basines, 
2 mediastinal nodal basins) are considered distant metastases.
5.4.2 Methods of measurements 
‚Ä¢CT and MRI are an essential part of the work-up to establish recurrence. Conventional CT with 
IV contrast and MRI gadolinium should be performed with contigu ous cuts of [ADDRESS_704016] should be performed using a 3- or 5-m m contiguous reconstruction 
algorithm; this sp ecification applies to the tumors of the chest, abdomen and pel vis while head 
& neck tumors and those of the extremities usually require spec ific protocols. In each institute 
the same technique for CT/MRI should be used to characterize eac h new lesion.
‚àíFor subjects allergic to contrast media, they may have a CT perf ormed without contrast 
after discussion and agreement with the medical monitor
‚Ä¢PET alone will not be considered for the disease assessment. Co mplementary CT and/or MRI 
or biopsy must be performed in such cases.
‚Ä¢Cytology and/or histology are mandatory to confirm recurrence i n solitary or in doubtful 
lesions, cutaneous, subcutaneous or lymph node lesions. Histolo gical or cytologi cal evidence 
of recurrence should be attempted in all cases except for brain metastases when safe and 
clinically feasible.  An example when obtaining a biopsy to con firm recurrence may not be 
safe and clinically feasible is brain metastases.
‚Ä¢Clinically detected new lesions:
‚àíSuperficial cutaneous lesions: the neoplastic nature must be confirmed by
[CONTACT_3973]/histology.
‚àíDeep subcutaneous lesions and lymph node lesions s hould be documen ted by [CONTACT_540132]/cytological evidence should be attempted. In a bsence of pathology report, 
lesion recurrence will be documented with a CT scan/MRI.
‚Ä¢Tumor markers or auto-antibodies  alone cannot be used to assess  recurrence.
5.4.[ADDRESS_704017] date when recurrence was observed is taken into account regardless the method of 
assessment. Therefore recurrence will be declared for any lesion  when:
‚Ä¢Only imaging was performed and recurrence c onfirmed
Revised Protocol No: 06
Date: 14-Oct-2020 83
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚Ä¢Only pathology was done and malignancy confirmed (in solitary o r in doubtful lesions, 
cutaneous, subcutaneous or lymph node lesions)
‚Ä¢Both pathology and imaging were  done and recurrence/malignancy confirmed. In this case, the 
date of whichever examination comes first is considered the date of recurrence.
Pathology reports of biopsies confirming recurrence should be s ent to a central vendor.
Note: for documentation, the date of recurrence is the date tha t the pathology and/or imaging 
confirms recurrence--not the date that the information was comm unicated to the subject.
 
 
 
 
 
 
 
 
 
 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704018] 
commonly used QoL instrument in melanoma clinical studies. It i s a 30-item instrument that has 
gained wide acceptance in oncology clinical studies. The EORTC QLQ-C30 comprises 
5 functional scales (physical functioning, cognitive functioning , emotional functioning, social 
functioning and global quality of life) as well as nine symptom  scales (fatigue, pain, 
nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Except for the overall health status and global quality of life items, responses for all 
items are 4 point categorical scales ranging from 1 (Not at all) to 4 (Very much). The overall health 
status/quality of life responses are 7-point Likert scales. 
Revised Protocol No: 06
Date: 14-Oct-2020 89
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All 
PRO instruments will be administered during on-study, and f ollow-up phases as outlined in 
Table 5.1-2 , Table 5.1-3 , Table 5.1-4 , Table 5.1-5 , Table 5.1-6 , and Table 5.1-7 , respectively, to 
all randomized subjects. 
Healthcare resource utilizatio n data (eg, hospi[INVESTIGATOR_602], non -protocol specified medical visits, 
diagnostics, etc) w ill be collected for all ra ndomized subjects. The resource ut ilization capture is 
specific to hospi[INVESTIGATOR_540105] a nd non-protoco l specified visits related to study
therapy. Resource u tilization questions will be asked as outlin ed in Tables of Section 5.[ADDRESS_704019] alread y been analyzed.
 
 
 
 
  
Revised Protocol No: 06
Date: 14-Oct-2020 90
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
 
 
 
6
ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subje ct administered study drug and that 
does not necessarily have a causal relationship with this treat ment. An AE can therefore be any 
unfavorable and unintended sign (s uch as an abnormal laboratory  finding), symptom , or disease 
temporally associated with the use of study drug, whether or no t considered related to the study 
drug.
The causal relationship to study drug is determined by a physician and should be used to assess all 
adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between stud y drug administration and 
the AE.
Not related: There is not a reasonable causal relationship betw een study drug 
administration and the AE. 
The term "reasonable causal relationship" means there is eviden ce to suggest a causal relationship. 
Adverse events can be spontaneously reported  or elicited  during open-ended questioning, 
examination, or evaluation of a subject. (In order to prevent r eporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
6.1 Serious Adverse Events
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: 
‚Ä¢results in death
‚Ä¢is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically m ight have caused death if it were 
more severe)
‚Ä¢requires inpatient hospi[INVESTIGATOR_20345] (see NOTE
below)
‚Ä¢results in persistent or significant disability/incapacity
‚Ä¢is a congenital anomaly/birth defect 
‚Ä¢is an important medical event (defined as a medical event(s) th at may not be immediately life-
threatening or result in death or hospi[INVESTIGATOR_313], based up on appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] t o prevent one of the other serious outcomes listed in the defin ition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room  or at 
home for allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
Revised Protocol No: 06
Date: 14-Oct-2020 91
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
hospi[INVESTIGATOR_059].) Potential drug i nduced liver injury (DILI) is  also considered an important 
medical event. (See Section 6.6 for the definition of potential DILI.)
Suspected transmission of an infect ious agent (eg, pathogenic o r nonpathogenic) via the study d rug 
is an SAE. 
Although pregna ncy, overdose, cancer, a nd potential drug induce d liver injury (DILI) are not 
always serious by [CONTACT_540133], these events must be h andled as SAEs. (See Section 6.1.1
for reporting pregnancies).Any component of a study endpoint that is considered related to  study therapy (eg, death is an 
endpoint, if death o ccurred due to anaphylaxis, anaphylaxis mus t be reported) should be reported 
as SAE (see Section  6.1.1 for reporting details).
NOTE : 
The following hospi[INVESTIGATOR_193581] c linical studies: 
‚àía visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that does not result 
in admission (unless considered an important medical or life-th reatening event)
‚àíelective surgery, planned prior to signing consent
‚àíadmissions as per protocol for a planned medical/surgical proce dure
‚àíroutine h ealth assessment requi ring admission for baseline/trending of h ealth status (eg, 
routine colonoscopy)
‚àímedical/surgical admission other than to remedy ill h ealth a nd planned prior to entry into 
the study. Appropriate documentation is required in these cases
‚àíadmission encountered for another life circumstance that carrie s no bearing on health status 
and requires no medical/surgical intervention (eg, lack of hous ing, economic inadequacy, 
caregiver respi[INVESTIGATOR_040], family circumstances, administrative reason) .
‚àíAdmission for administration of anticancer therapy in the absen ce of any other SAEs 
(applies to oncology protocols)
6.1.1 Serious Adverse Event Collection and Reporting
Sections 5.6.1 a nd 5.6.2 in the Investigator Brochure (IB) repr esent the Reference Safety 
Information to determine expectedness of serious adverse events  for expedited reporting. 
Following the subject‚Äôs or the legal representative‚Äôs written consent to participate in the study, all 
SAEs, whether related or not related to st udy drug, must be collected, including those thought to 
be associated with protocol-specified procedures. All SAEs must be collected that occur during 
the screening period and within [ADDRESS_704020] be collected tha t relate to any later protocol-
specified procedure (eg. a follow-up skin biopsy). 
Revised Protocol No: 06
Date: 14-Oct-2020 92
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
The investigator should report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure. 
An SAE report should be completed for any event where doubt exi sts regarding its seriousness. 
If the investigator believes that an SAE is not related to stud y drug, but is potentially related to the 
conditions of the study (such as withdrawal of previous therapy  or a complication of a study 
procedure), the relationship should be specified in the narrati ve section of the SAE Report Form.
SAEs, whether related or not related to study drug, and pregnan cies must be reported to BMS (or 
designee) within [ADDRESS_704021] b e recorded on the SAE Report
Form; pregnancies on a Pregna ncy Surveillance Form (electronic or paper forms). The preferred 
method for SAE data reporting collection is through the eCRF.  The paper SAE/pregnancy 
surveillance forms are onl y intended as a back-up option when the eCRF system is not functioning.  
In this case, the paper forms are to be transmitted via email o r confirmed facsimile (fax) 
transmission to:SAE Email Address: Refer to Contact [CONTACT_20491].
SAE Facsimile Number:  Refer to Contact [CONTACT_20491].
For studies capturing SAEs through electronic data capture (EDC ), electronic submission is the 
required method for reporting. The paper forms should be used a nd submitted immediately, only 
in the event the electronic sy stem is unavailable for transmiss ion. When paper forms are used, the 
original paper forms are to remain on site.
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact 
[CONTACT_20491].
If only limited information is  initially available, follow-up r eports are required. (Note: Follow-up 
SAE reports should include the same investigator term(s) initia lly reported.) 
If an ongoing SAE changes in its intensity or relationship to s tudy drug or if n ew information 
becomes available, a follow-up SAE report should be sent within  24 hours to the BMS (or 
designee) using the same procedure used for transmitting the in itial SAE report.
All SAEs should be followed to resolution or stabilization.
6.2 Nonserious Adverse Events
Anonserious adverse event is an AE not classified as serious.
6.2.1 Nonserious Adverse Event Collection and ReportingThe collection of nonserious AE (not only those deemed to be treatment-related) i nformation 
should begin at initiation of study drug and continue until [ADDRESS_704022] dose of study 
drug . Non-serious AE information should also be collected from the start of a placebo lead-in 
period or other observational period intended to establish a baseline status for the subjects.
Nonserious AEs should be followed to resolution or stab ilization, or reported as SAEs if they 
become serious (see Section 6.1.1 ). Follow-up is also required for nonserious AEs that cause 
withholdi ng or discontinuation of study drug and for those present at th e end of study treatment as 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704023] be recorded and  described on the nonserious AE 
page of the CRF (paper or electronic). 
Completion of supplemental CRFs may be requested for AEs and/or laboratory abnormalities that 
are reported/identified during the course of the study. Every adverse event must be assessed by [CONTACT_540134]. For events which are 
potentially immune mediated, additional information will be coll ected on the subject‚Äôs case report 
form.
6.[ADDRESS_704024] result abnormalities should be ca ptured on the nonserious AE CRF 
page or SAE Report Form (paper or electronic) as appropriate:
‚Ä¢Any laboratory test result that is clinically significant or me ets the definition of an SAE 
‚Ä¢Any laboratory test result abnormality that required the subjec t to have study drug omitted or 
discontinued 
‚Ä¢Any laboratory test result abnorm ality that required the subjec t to receive specific corrective 
therapy.
It is expected that wherever possible, the clinical rather than laboratory term would be used by [CONTACT_35867] (eg, anemia versus low hemoglobin value) .
6.[ADDRESS_704025] immed iately notify the BMS Medical 
Monitor/designee of this event and complete and forward a Pregn ancy Surveillance Form to BMS 
Designee within [ADDRESS_704026] cases, the study drug will be permanently discontinued in an appropriate manner (eg, dose tapering if necessary for subject safety).
In the rare event that the benefit of continuing study drug is thought to outweigh the risk, after 
consultation with BMS, the pregnant subject may continue study drug after a thorough discussion 
of benefits and risk with the subject 
Protocol-required procedures fo r study disconti nuation and follo w-up must be performed on the 
subject unless contraindicated by [CONTACT_8663] (eg, x-ray studies) . Other appropriate pregnancy 
follow-up procedures should be considered if indicated.The investigator must immediately notify the BMS (or designee) Medical Monit or of this event 
and complete and forward a Pre gnancy Surveillance Form to BMS ( or designee) within 24 hours 
of awareness of the event and in accordance with SAE reporting procedures described in 
Section 6.1.1.  
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704027] be 
reported as an SAE (see Section 6.1.1 for reporting details.).
6.6 Potential Drug Induced Liver Injury (DILI)Wherever possible, t imely confirmation of initial liver-related  laboratory abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occ urrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
Potential drug induced liver injury is defined as: 
‚Ä¢AT (ALT or AST) elevation > [ADDRESS_704028]
AND
‚Ä¢Total bilirubin > [ADDRESS_704029], without init ial findings of cholestasis ( elevated serum alkaline 
phosphatase),AND
‚Ä¢No other immediately apparent possible causes of AT elevation a nd hyperbilirubinemia, 
including, but not limi ted to, viral hepatitis, pre-existing ch ronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
6.7 Other Safety Considerations
Any significant worsening noted during interim or final physica l examinations, electrocardiogram, 
x-ray filming, any other potential safety assessment required o r not required by [CONTACT_61892] a nonserious or serious AE, as appropriate,  and reported accordingly. 
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL 
COMMITTEES
A Data Monitoring Committee (DMC) w ill be established to provide oversight of safety and 
efficacy considerations in protocol CA209238. Additionally, the  DMC will provide advice to the 
sponsor regarding actions the co mmit tee deems necessary for the continuing protection of subjects 
enrolled in the study. The DMC w ill be charged with assessing s uch actions in light of an 
acceptable benefit/risk profile for nivolumab and ipi[INVESTIGATOR_125]. The  DMC will act in an advisory 
capacity to BMS and will moni tor subject safety and evalu ate the available efficacy data for the 
study. The oncology therapeutic area of BMS has primary respons ibility for design and conduct 
of the study. 
Revised Protocol No: 06
Date: 14-Oct-2020 95
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
When required, adjudicated events will be submitted to the DMC and Health Authori ties for review 
on a specified timeframe in accordance with the adjudication do cumentation.
The final DMC meeting occurred on 28-Apr-2020. 
8 STATISTICAL CONSIDERATIONS
As of Revised Protocol 06, all planned analyses were conducted based on the 48-month minimum 
follow-up database lock, whic h occurred in Jan-2020. No additio nal formal efficacy analyses will 
be conducted for new ly collected efficacy d ata. Explor atory analysis on these new efficacy d ata 
will be conducted using similar analyses described in the Clinical Study Report (CSR) Statistical 
Analysis Plan (SAP) for the 48-month minimum follow-up database l ock. Exploratory analyses 
will be performe d, eg, every other year, though the analysis schedule might be adjusted based on 
the additional number of events accumulated.
8.[ADDRESS_704030] at an overall alpha level of 0.05 (two-
sided) with approximately 85% power. The number of events and p ower were calculated assuming 
a delayed treatment effect and cure fraction. 
Approximately [ADDRESS_704031] been randomized to the two trea tment arms in a 1:1 ratio. Based 
on current accrual and revised pi[INVESTIGATOR_13959]-wise accrual r ate assumptions, accrual duration was 7.5 
months. Taking into account the actual AJCC disease stage distr ibution, slower event rate, higher 
cure rates, and some early drop-out, the original planned 507 e vents might not be reached by [CONTACT_540135] (ie, after all sub jects have a minimum of 36 months of follow-up). 
Approximately [ADDRESS_704032] 85% 
power to detect a hazard rati o of 0.75 (critical hazard ratio o f 0.83) with an overall type I error of 
0.05 (two-sided). Sample size calculations for this study desig n were done using EAST 6 (v 6.3.1) 
and R.
An interim analysis of RFS will take place after all sub jects have a minimum of [ADDRESS_704033] numb er of RFS events at interim using 
Lan-DeMets alpha spending function with O‚ÄôBrien-Fleming boundar ies. With an interim RFS 
analysis at 350 RFS events (about 78% information fraction), the critical h azard ratio would be 
0.78 and the type I error would be 0.022 (two-sided). The type I error to be used for final RFS 
analysis would be 0.043 (two-sided). 
8.2 Populations for Analyses
‚Ä¢All enrolled subjects: All subjects who signed an informed cons ent form and were registered 
into the IVRS.
‚Ä¢All randomized subjects: All subjects who were randomized to an y treatment arm in the study. 
‚Ä¢All treated subjects: All subjects who received any study drug nivolumab or ipi[INVESTIGATOR_540106].
Revised Protocol No: 06
Date: 14-Oct-2020 96
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚Ä¢
 
 
8.3 Endpoints
8.3.1 Primary Endpoint(s)
The primary endpoint is RFS. The primary endpoint of RFS will b e programmatically determined 
based on the disease recurrence date provided by [CONTACT_540136] r andomization and the da te of first recurre nce (local, regional or distant 
metastasis), new primary melanoma, or death (whatever the cause) , whichever occurs first. (Note: 
a subject who dies without reported recurrence will be consider ed to have recurred on the date of 
death.) For subjects who r emain aliv e and whose disease has not rec urred, RFS w ill be censored 
on the date of last evaluable disease assessment. For those subj ects who remained alive and had 
no recorded post-randomization tum or assessment, RFS will be ce nsored on the day of 
randomizatio n. Censoring rules for the primary analysis of RFS are presented in  Table 8.3.1-1 .
Revised Protocol No: 06
Date: 14-Oct-2020 97
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
Table 8.3.1-1: Censoring Scheme for Primary Definition of RFS
Situation Date of Event or Censoring Outcome
Recurrence (local, regional, distant, new primary 
melanoma)Date of first recurrence Event
Death without recurrence Date of death Event
Disease at baseline Date of randomization Event
No baseline disease assessment Date of randomization Censored
No on-study dis ease assessments and no death Date of randomizati on Censored
No recurrence and no death Date of last evaluable disease 
assessmentCensored
New anticancer therapy, tumor-directed 
radiotherapy, or tumor-directed surgery received without recurrence reported prior to or on the 
same day of disease assessmentDate of last evaluable disease 
assessment prior to or on the same 
date of initiation of subsequent 
therapyCensored
Second non-melanoma primary cancer reported prior or on the same day of di sease assessmentDate of last evaluable disease 
assessment prior to or on the same 
date of diagnosis of second non-
melanoma primary cancerCensored
RFS, recurrence-free survival
As of Revised Protocol 06, since no study-specified surveillance assessments are to be collected 
beyond Year 5, the censoring rules for defining RFS will be diff erent from the primary definition 
above. RFS will be defined as the time between the date of rand omization and the date of first 
recurrence (local, regional, or distant metastasis), new primary  melanoma, or death (whatever the 
cause), whichever occurs first. (Note: A subject who dies withou t reported recurrence will be 
considered to have recurred on the date of death.) For subjects  who remain alive and whose disease 
has not recurred, RFS will be censored on the last date the sub ject was known to be alive. 
Censoring rules for the exploratory analysis of RFS are presente d in Table 8.3.1-2.
Table 8.3.1-2: Censoring Sch eme for Definition of RFS
Situation Date of Event or Censoring Outcome
Recurrence (local, regional, distant, new primary 
melanoma)Date of first recurrence Event
Death without recurrence Date of death Event
Disease at baseline Date of randomization Event
No baseline disease assessment Date of randomization Censored
No on-study dis ease assessments and no death Date of randomizati on Censored
No recurrence and no death Date last known to be alive Censored
New anticancer therapy, tumor-directed 
radiotherapy, or tumor-directed surgery received Date of initiation of subsequent 
therapyCensored
Revised Protocol No: 06
Date: 14-Oct-2020 98
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
Table 8.3.1-2: Censoring Scheme for Definition of RFS
Situation Date of Event or Censoring Outcome
without recurrence reported prior to or on the 
same day of disease assessment
Second non-melanoma primary cancer reported prior or on the same day of di sease assessmentDate of diagnosis of second non-
melanoma primary cancerCensored
RFS, recurrence-free survival
8.3.2 Secondary Endpoint(s)
The first secondary endpoint (OS) is defined as the time betwee n the date of r andomization and 
the date of death. For subjects without documentation of death,  OS will be censored on the last 
date the subject was known to be alive. OS w ill be followed continuously wh ile subjects are on 
the study drug and every [ADDRESS_704034]  after subjects discontinue the 
study drug.
The second secondary endpoint (to assess the safety and tolerab ility o f nivolumab a nd ipi[INVESTIGATOR_125]) 
will be measured by [CONTACT_20497], serious adverse events, deaths, and laboratory 
abnormalities.
The third secondary endpoint (to evaluate PD-L1 expression as a  predictive biomarker) will be 
measured by [CONTACT_540137]-L1 expression level.
The fourth secondary objective (to evaluate HRQo L) will be measured by [CONTACT_540138]-QLQ-C30 global health status/QoL composit e scale and by [CONTACT_540139]-C30 scales in all rand omized subjects.  
 
 
 
 
 
 
 
 
 
Revised Protocol No: 06
Date: 14-Oct-2020 99
7.0 Approved 930084592 7.0v

Clinical Protocol CA209238
BMS-936558 nivolumab
8.4 Analyses
8.4.1 Demographics and Baseline Characteristics
Demographic and baseline characteristics will be summarized by [CONTACT_540140].
8.4.2 Efficacy Analyses
[IP_ADDRESS] Primary Endpoint Methods
The primary RFS analyses will be conducted using a two-sided lo g-rank test stratified by [CONTACT_4002]-L1 
status and Stage at screening in randomized subjects. The hazar d ratio and corresponding 
two-sided (1-adjusted Œ±)% CI will be es timated using a Cox proportional hazards model, with 
treatment group as a single covariate, stratified by [CONTACT_941] a bove factors. RFS curves, RFS medians 
with 95% CIs, and RFS rates at 6, 12, 18, 24 and 36 months with 95% CIs will be estimated using 
Kaplan-Meier methodology.
[IP_ADDRESS] Secondary Endpoint Methods
The secondary OS analysis will be conducted using a two-sided l og-rank test stratified by [CONTACT_4002]-L1 
status and Stage at screening in randomized subjects. The hazard  ratio and corresponding 
two-sided (1-adjusted Œ±)% CI will be es timated using a Cox proportional hazards model, with 
treatment arm as a single covariate, stratified by [CONTACT_540141]. OS curves, OS medians with 
95% CIs and OS rates at 12 and 24 months with  95% CIs will be est imated using Kaplan-Meier 
methodology. 
To evaluate PD-L1 expression as a predictive biomarker, a Cox p roportional hazards model will 
be used to test the interaction b etween PD-L1 expression (posit ive vs negative) and treatment arm 
for the RFS endpoint. Additionally, RFS will be analyzed within  each PD-L1 e xpression subgroup 
(positive and negative ) including log-rank tests and hazard rat ios with corresponding confidence 
intervals. RFS curves and medians will be estimated using Kapla n-Meier methodology. These 
analyses will be descriptive a nd not adjusted for multiplicity. Other exploratory analyses, such as 
associations between PD-L [ADDRESS_704035] grade NCI CTCAE 
v 4.0 criteria.
 
 
 
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704036] one follow-up assessment.
All scales and single items are scored on a categorical scales and linearly transformed to 0-to-100 
scales with higher score s for a functional s cale representing higher levels of functioning, higher 
scores for the global health status/quality of life representin g higher levels of global health 
status/quality of life and higher scores for a symptom scale re presenting higher level of symptoms.
EORTC QLQ C-30 global health status/QoL composite scale data and  the remaining EORTC QLQ 
C-[ADDRESS_704037] number of RFS events using 
Lan-DeMets alpha spending function with O‚ÄôBrien-Fleming boundar ies. No interim analysis of 
OS will be performed at this time
If RFS is significant, the trial will continue and OS w ill be tested hierarchically. One formal OS 
interim analysis will be conducted at the time of the final RFS analysis. This formal comparison 
of OS will allow for early stoppi[INVESTIGATOR_540107]. The stoppi [INVESTIGATOR_540108]-DeMets alpha 
spending function with O‚ÄôBrien-Flemi ng boundaries. 
The final OS analysis will take place after all subjects have a  minimum of [ADDRESS_704038] approximately 55.5 months from the start o f the study. At the time of the 
final OS analysis, 302 events are expected ensuring approximatel y 88% overall power to detect a 
hazard ratio of 0.70. Details of the OS modeling will be presen ted in the SAP.
In addition to the formal planned interim analysis for OS, the DMC will have access t o periodic 
unblinded interim reports of efficacy and safety to allow a ris k/benefit assessment. Details will be 
included in the DMC charter.
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704039] be discussed with, and be prepared by, BMS. The investigat or should not implement any 
deviation or change to the protocol without prior review and do cumented approval/favorable 
opi[INVESTIGATOR_5698]/IEC of an amendment, except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to elimin ate an immediate hazard(s) prior to 
obtaining IRB/IEC approval/favorable opi[INVESTIGATOR_1649], as soon as possib le the deviation or change will be 
submitted to:
‚Ä¢IRB/IEC for review and approval/favorable opi[INVESTIGATOR_1649]
‚Ä¢BMS
‚Ä¢Regulatory Authority(ies), if required by [CONTACT_20507](s)/IEC(s) must be 
sent to BMS.
If an amendment substantially a lters the study design or increa ses the potential risk to the subject: 
(1) the consent form must be revised and submitted to the IRB(s )/IEC(s) for review and 
approval/favorable opi[INVESTIGATOR_1649]; (2) the revised form must be used t o obtain consent from subjects 
currently enrolled in the study if they are affected by [CONTACT_20508]; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment .
If the revision is done via an administrative letter, investiga tors must inform their IRB(s)/IEC(s).
9.1.[ADDRESS_704040] copi[INVESTIGATOR_20350]. 
Revised Protocol No: 06
Date: 14-Oct-2020 102
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
[IP_ADDRESS] Source Documentation
The Investigator is responsible for ensuring that the source dat a are accurate, legible, 
contemporaneous, original and attr ibutable, whether the data are hand-written on paper or entered 
electronically. If source  data are created (first entered), modified, maintained, arc hived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such s ystems must be compliant with all 
applicable laws and regulations governing use of elect ronic rec ords and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments , and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copi[INVESTIGATOR_014]. A ce rtified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes a nd information as the original. 
9.1.3 Investigational Site Training
[COMPANY_016] will provide quality investig ational staff training prior to study initiation. 
Training topi[INVESTIGATOR_20351]: GCP, AE re porting, study details and procedure, 
electronic CRFs, study documen tation, informed consent, and enro llment of WOCBP.
9.[ADDRESS_704041] BMS prior to destroying 
any records associated with the study.
BMS will notify the investigator when the study records are no longer needed.
If the investigator withdraws from the study (eg, relocation, r etirement), the records sh all be 
transferred to a mutually agreed upon designee (eg, another inv estigator, IRB). Notice of such 
transfer will be given in writing to BMS.
9.2.[ADDRESS_704042] (inventoried and dispensed) is maintain ed at the study site. Records or logs 
must comply with applicable regulations and guidelines and shou ld include:
‚Ä¢amount received and placed in storage area
‚Ä¢amount currently in storage area
‚Ä¢label identification number or b atch number 
‚Ä¢amount dispensed to and returned by [CONTACT_6992], including uni que subject identifiers
‚Ä¢amount transferred to another area/site for dispensing or storag e
Revised Protocol No: 06
Date: 14-Oct-2020 103
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
‚Ä¢nonstudy disposition (eg, lost, wasted) 
‚Ä¢amount destroyed at study site, if applicable
‚Ä¢amount returned to BMS
‚Ä¢retain samples for bioavailability/bioequivalence, if applicabl e 
‚Ä¢dates and initials of person responsible for Investigational Pr oduct dispensing /accountability, 
as per the Delegation of Authority Form.
BMS will provide forms  to facilitate inventory control if the i nvestigational site does not have an 
established system that meets these requirements.
9.2.[ADDRESS_704043] safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the BMS electronic data capture tool, electroni c CRFs will be prepared for all data 
collection fields except for fields specific to SAEs and pregna ncy, which will be reported on the 
paper or electronic SAE form and Pregnancy Surveillance form, r espectively. Spaces may be left 
blank only in those circumstances permitted by [CONTACT_3449]-specific C RF completion guidelines 
provide d by [CONTACT_20444]. 
The confidentiality of records that could identify subjects mus t be protected, respecting the privacy 
and confidentiality rules in accorda nce with the applicable reg ulatory requirement(s).
The investigator will maintain a signature [CONTACT_35899]/or corrections on CRFs. 
The completed CRF, including any paper or electronic SAE/pregnancy CRFs, must be promptly 
reviewed, signed, and dated by [CONTACT_441910] a subinvestigator and 
who is delegated this task on the D elegation of Authority Form. For electronic CRFs, review and 
approval/signature [CONTACT_61912]. The 
investigator must retain a copy of the CRFs including records o f the changes and corrections.
Each individual electronically signing electronic CRFs must mee t BMS training requirements and 
must only access the BMS electronic data capture tool using the unique user account provided by 
[CONTACT_20444]. User accounts are not to be shared or reassigned to other individuals.
9.[ADDRESS_704044]  be selected to sign the CSR. 
Revised Protocol No: 06
Date: 14-Oct-2020 104
7.0 Approved 930084592 7.0v
Clinical Protocol CA209238
BMS-936558 nivolumab
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
‚Ä¢Subject recruitment (eg, am ong the top quartile of enrollers)
‚Ä¢Involvement in trial design
‚Ä¢Other criteria (as determined by [CONTACT_3476]).
The data collected during this study are confidential and propr ietary to BMS. Any publications or 
abstracts arising from this study must a dhere to the publicatio n requirements set forth in the clinical 
trial agreement (CTA) governing [Study site or Investigator] pa rticipation in the study. These 
requirements include, but are  not limited to, submitting propos ed publications to BMS at the 
earliest practicable time prior to submission or presentation and otherwise within the time period 
set forth in the CTA.
10 GLOSSARY OF TERMS
Term Definition
Complete Abstinence Complete Abstinence is defined as complete a voidance of 
heterosexual intercourse and is an acceptable form of 
contraception for all study drugs. This also means that 
abstinence is the preferred and usual lifestyle of the patient.  
This does not mean periodic abstinence (eg, calendar, ovulation, sym ptothermal, profession of abstinence for entry 
into a clinical trial, post- ovulation met hods) and wit hdrawal, 
which are not acceptable methods of contraception. Women 
must continue to have pregnancy tests. Acceptable alternate 
methods of highly or less effective contraception‚Äôs must be 
discussed in the event that the subject chooses to forego 
complete abstinence.
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704045] aspartate aminotransferase
AT aminotransaminases
AUC(INF) area under the concentration-time curve from time zero extrapolated to 
infinite time
HCG human chorionic gonadotrophin
BMS [COMPANY_016]
BP blood pressure
BUN blood urea nitrogen
CBC complete blood count
CI confidence interval
CL clearance
cm centimeter
Cmax maximum observed concentration
CMV cytomegalovirus
CNS central nervous system
CR Complete response 
CRF Case Report Form, paper or electronic
CSR clinical study report
CT computed tomography
CTA Clinical trial agreement 
CTCAE common terminology criteria for adverse events
CTLA-4 cytotoxic T lymphocyte associated antigen-4
DILI drug-induced liver injury
dL deciliter
DLT dose limiting toxicity
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704046]
ITSM immunoreceptor tyrosine-based switch motif
IU International Unit
IV intravenous
IVRS Interactive Voice Response System
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704047] 
MDSC Myeloid derived suppressor cells 
mg milligram
mL milliliter
MLR mixed lymphocyte reaction
MRI Magnetic resonance imaging 
MTD maximum tolerated dose
MU millio n units
Œºg microgram
N number of subjects or observations
N/A not applicable
NSCLC non-small cell l ung cancer
NED no evidence of disease
ng nanogram
NIMP non-investigational medicinal products 
Obs. Observation
ORR Objective response rate 
OS overall survival
PBMC peripheral blood mononuclear cells
PD-1 programmed death receptor-1
PFS Progression free survival
PK pharmacokinetics
PPK Populat ion pharmacokinetic 
PR Partial response 
PRO Patient Reported Outcome
QoL Quality of Life 
QLQ-C30 Quality of Life Questionnaire- Core
Revised Protocol No: 06
Date: 14-Oct-[ADDRESS_704048] upper limit of normal
US [LOCATION_002]
VAS visual analog rating scale 
Vz Volume of distribution of terminal phase (if IV and if multi- exponential 
decline)
WBC white blood cell
WOCBP women of childbearing potential
WPAI:GH Work Productivity and Activity Impairment : General Heal th
Revised Protocol No: 06
Date: 14-Oct-2020 109
7.0 Approved 930084592 7.0v